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ABSTRACT
INNATE IMMUNITY IN DEGENERATIVE DISEASES OF THE RETINA AND BRAIN
Jacob Khan Sterling
Joshua L. Dunaief and Qi N. Cui
Innate immunity plays a critical role in degenerative diseases of the central nervous system (CNS).
However, many of the molecular pathways by which innate inflammation contributes to individual
diseases remain unknown. Herein, we use a combination of primary cell culture, in vivo animal
studies and human data to explore two distinct pathways of neuroinflammation. The first, focuses
on the role of reactive astrocytes as mediators of innate inflammation and neurodegeneration in
glaucoma. The second, highlights the role of nutritional immunity, a division of the innate immune
system, in iron dysregulation observed across multiple CNS diseases including age-related
macular degeneration and Parkinson’s disease. Together these data highlight the multiple
mechanisms by which maladaptive activation of innate immunity can contribute to CNS dysfunction
and identify new targets for therapeutic intervention.
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CHAPTER 1: INTRODUCTION
Reactive Astrogliosis in Glaucoma
Glaucoma: Epidemiology & Current Therapies
Glaucoma is characterized by the death of retinal ganglion cells (RGCs) and is the leading cause
of irreversible blindness globally. Primary open angle glaucoma (POAG) is the most prevalent form
and is projected to affect approximately 80 million people worldwide by 20401. In about 60% of
cases, POAG is associated with ocular hypertension2. All available therapies for glaucoma target
IOP reduction through either medical or surgical means. However, disease progression can
continue despite IOP normalization, and aggressive IOP lowering is associated with visionthreatening complications3,4. New therapies, targeting mechanisms of glaucoma beyond elevated
IOP, are urgently needed to prevent permanent vision loss in patients who have exhausted existing
treatment options.
Reactive Astrocytes
Reactive astrocytes are observed in multiple neurodegenerative diseases5,6. In healthy neural
tissue, astrocytes serve a wide variety of roles - contrbuting to neurotransmitter recycling, neuronal
metabolism, and formation of the blood-brain and blood-retina barriers7,8. In the retina, astrocytes
are found exclusively in the ganglion cell layer, comingled with RGCs9. In response to both local
and systemic stimuli, astrocytes can adopt reactive forms, A1 pro-inflammatory or A2
neuroprotective, both of which have been transcriptionally defined10. A1 reactive astrocytes lose
their phagocytic capacity as well as their ability to promote synapse formation and function. At the
same time, A1 astrocytes gain pro-inflammatory and neurotoxic functions5,10. In contrast, A2
astrocytes, observed in post-ischemic tissue, upregulate neurotrophic factors, promoting a
neuroprotective environment10. While A1 astrocytes have been implicated in multiple
neurodegenerative diseases5,6, their contribution to glaucoma is only beginning to be explored.
In the brain and the retina, neurotoxic A1 astrocytes are induced by microglial release of proinflammatory cytokines IL-1α, TNF-α, and C1q5. Strong links exist between these three cytokines
and glaucoma. IL1A and TNF polymorphisms are associated with primary open angle glaucoma11–
13
. TNF-α protein levels are elevated in the vitreous, retina, and optic nerves of glaucomatous
eyes14. In the DBA/2J mouse model of hypertensive glaucoma, C1qa mRNA levels are associated
with disease progression15, and C1q inhibition is sufficient to prevent early RGC synapse loss and
RGC death16–18. Multiple publications have also demonstrated C1q upregulation in glaucomatous
human eyes19,20. Although IL-1α, TNF-α and C1q have been independently implicated in glaucoma,
it is not known whether they act in concert to induce A1 astrocyte reactivity in glaucomatous retinas.
Glucagon-Like Peptide 1 Receptor Agonists
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that regulates blood glucose, weight, and
satiety. Agents that increase GLP-1 receptor (GLP-1R) signaling, including GLP-1 analogs and
dipeptidyl peptidase 4 (DPP-IV) inhibitors, have been developed for the treatment of type 2 diabetes
mellitus. GLP-1R agonists first gained FDA-approval in 2005 and include exenatide, liraglutide,
albiglutide, dulaglutide, semaglutide, and lixisenatide. In addition to their effects in the periphery,
GLP-1R agonists cross the blood-brain barrier and exert effects in the central nervous system,
influencing feeding behavior, cellular proliferation, mitochondrial function, and neuroinflammation21.
GLP-1R agonists are neuroprotective in mouse models of neurodegenerative diseases including
Parkinson’s6 and Alzheimer’s22 disease. A randomized control trial of 45 patients with Parkinson’s
disease found a statistically significant improvement in both motor and non-motor deficits among
subjects treated with exenatide23. In a randomized control trial targeting Alzheimer’s disease,
liraglutide improved cognitive function24. NLY01 is a long-acting GLP-1R agonist with an extended
half-life and favorable blood-brain barrier penetration6. In mouse models of Parkinson’s disease
(PD), A1 astrocytes contribute to dopaminergic cell death and poor motor phenotypes. NLY01 has
been shown to reduce microglial production of C1q, TNF-α, and IL-1α, thereby blocking A1
1

astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in
mouse models of PD6.
We hypothesized that GLP-1R agonist treatment prevents A1 astrocyte activation in glaucoma,
reducing RGC death.
Nutritional Immunity in the Central Nervous System
Cellular Iron Import & Export (Fig. 1-1)
The vast majority of serum iron is in the ferric (Fe3+) state bound to transferrin (Tf), termed
transferrin-bound iron (TBI). A small minority of circulating iron is ferrous (Fe2+) and non-transferrin
bound (NTBI). TBI and NTBI are imported into cells via distinct mechanisms14. TBI binds transferrin
receptor (TfR) and the complex is endocytosed. Endosome acidification results in the release of
ferric iron which is reduced to the ferrous state by Steap3, an endosomal ferrireductase, before
being transported by divalent metal transporter 1 (Dmt1) into the cytosol25. NTBI is transported into
the cytosol directly from the extracellular environment by Dmt125, Zip826 or Zip1426,27.
Ferroportin (Fpn) is the only known mammalian iron exporter. Ferrous iron passes through Fpn
before being oxidized by ceruloplasmin (Cp) or hephaestin (Heph) and binding extracellular Tf. The
primary regulator of cellular iron efflux is hepcidin (Hepc), a secreted peptide hormone that triggers
the internalization and degradation of Fpn14.
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Figure 1-1. Schematic of cellular iron transport. (A) Iron import. (B) Iron export.
Nutritional Immunity, Inflammation and Iron Homeostasis
Iron is essential for life. Under physiological conditions, iron can accept and donate electrons,
serving as a cofactor in fundamental biochemical processes such as oxidative phosphorylation and
DNA repair25. However, iron’s very source of utility is also its source of toxicity. By toggling between
oxidation states, ferrous iron can react with hydrogen peroxide to form reactive oxygen species
(ROS)26–28. These ROS modify intracellular macromolecules such as DNA, lipids, and proteins,
leading to cell dysfunction and death29,30. Given iron’s essential role as an enzymatic cofactor for
both eukaryotic and prokaryotic organisms, control of iron is a critical component of nutritional
immunity, the branch of the innate immune system which regulates the availability of essential
elements to pathogens31–33. As part of the immune response to extracellular microbes, eukaryotic
cells sequester iron by increasing iron import and decreasing iron export to starve extracellular
pathogens of the iron necessary for their survival31–33. We term this pathway the cellular iron
sequestration response (CISR).
Parkinson’s Disease & Iron
Parkinson’s disease (PD) is characterized by the preferential death of dopaminergic (DA) neurons
in the substantia nigra (SN)45. The loss of DA neurons leads to characteristic motor deficits
2

including slowness of movement, tremor and rigidity46,47. In addition to the loss of DA neurons,
widespread pathology throughout the nervous system contributes to non-motor features of PD
including autonomic, olfactory, and cognitive symptoms48. Accumulation of α-synuclein (α-syn)
aggregates drives the pathogenesis and neurodegeneration in most forms of PD49 through both
cell-autonomous and non-cell autonomous mechanisms of neuron death50. Reactive microglia are
known to proliferate and promote a pro-inflammatory environment in PD and contribute to the
neurodegeneration in a non-cell autonomous fashion51,52. Moreover, it is well known that iron
accumulates in dopaminergic neurons of the SN of PD brains53,54. Yet, the molecular mechanisms
accounting for the accumulation of iron in PD are poorly understood.
Retinal Iron & Age-Related Macular Degeneration
Disruption of iron homeostasis in multiple diseases is associated with ocular manifestations. In both
thalassemia55 and Friedreich’s Ataxia56, abnormal retinal pigment epithelium (RPE) cells exhibit
iron accumulation. In aceruloplasminemia, loss of ceruloplasmin leads to iron accumulation in the
pancreas, brain and retina, leading to diabetes, dementia and retinal degeneration57. In select
cases, patients with aceruloplasminemia exhibit early onset age-related macular degeneration
(AMD)57. The analogous mouse model, lacking ceruloplasmin and homolog, hephaestin, (Cp/Heph
DKO) exhibits retinal iron accumulation and retinal degeneration with basal laminar deposits, RPE
and photoreceptor degeneration and subretinal neovascularization58. The ocular findings in
Cp/Heph DKO animals have been replicated in other animal models of iron accumulation, including
Hepcidin KO mice59 and Bmp6 KO mice60. Together these data suggest that iron accumulation
alone is sufficient for retinal degeneration.
Iron chelation therapy is protective against a diverse range of in vitro and in vivo insults. In vitro,
iron chelation reduces RPE hypertrophy and death triggered by peroxide, staurosporine and Fas
ligand61. In vivo, iron chelation is protective against photoreceptor and RPE degeneration
secondary to bright light62, sodium iodate63, and the RD6 mutation63. Thus, iron plays a detrimental
role in retinal degeneration secondary to a wide range of insults.
In AMD, iron accumulation is observed in the RPE64 and photoreceptors65. Furthermore, sequence
variants in iron regulatory genes are associated with increased AMD risk66–69. Recent work has
shown that intravenous injections of iron-sucrose in both wild-type mice, and a 43-year-old woman,
were associated with AMD-like retinopathy70. Multiple in vivo models have shown that retinal iron
overload is sufficient for retinal degeneration with AMD features58,59,63,71,72. In vitro and in vivo work
have established that elevated iron levels upregulate RPE synthesis and secretion of complement
component 3 (C3)73 and amyloid-β74, two components of AMD drusen. Despite a potential role for
iron in the pathogenesis of AMD, the mechanism of iron accumulation in AMD is unknown.
The CISR in Neurodegenerative Diseases
Chronic neuroinflammation contributes to multiple neurodegenerative diseases, including agerelated macular degeneration34, Parkinson’s disease35, and others36–38. Previous work has shown
that many of these same diseases are also associated with iron dyshomeostasis and cellular iron
accumulation39–44. We hypothesized that neuroinflammation activates a local CISR, triggering iron
dyshomeostasis and cellular iron accumulation relevant to a broad spectrum of neurodegenerative
diseases, including Parkinson’s disease and age-related macular degeneration.
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CHAPTER 2: NLY01 REDUCES RETINAL INFLAMMATION AND NEURON DEATH
SECONDARY TO OCULAR HYPERTENSION
Introduction
Glaucoma is characterized by the death of retinal ganglion cells (RGCs) leading to permanent
vision loss. It is the leading cause of irreversible blindness globally and is projected to affect
approximately 112 million people worldwide by 2040 (Tham et al., 2014). Elevated intraocular
pressure (IOP) is strongly associated with glaucoma, and reduction of IOP is the only therapeutic
mechanism available to slow disease progression. However, glaucoma can continue to progress
even in patients who achieve normal IOPs following medical and/or surgical treatments (Quigley,
2018). Therefore, new therapies are urgently needed to prevent vision loss in patients suffering
from glaucoma.
Reactive astrocytes are observed in multiple neurodegenerative diseases (Liddelow et al., 2017;
Yun et al., 2018). In healthy neural tissue, astrocytes serve a wide variety of roles. They contribute
to neurotransmitter recycling, neuronal metabolism, and formation of the blood-brain and bloodretina barriers (Clarke and Barres, 2013; Liddelow and Barres, 2017). In the retina, astrocytes are
found exclusively in the ganglion cell layer, comingled with RGCs (Vecino et al., 2016). In response
to both local and systemic stimuli, astrocytes can adopt reactive forms, A1 pro-inflammatory or A2
neuroprotective, both of which have been transcriptionally defined (Zamanian et al., 2012). A1
reactive astrocytes lose their phagocytic capacity as well as their ability to promote synapse
formation and function. At the same time, A1 astrocytes gain pro-inflammatory and neurotoxic
functions (Liddelow et al., 2017; Zamanian et al., 2012). In contrast, A2 astrocytes, observed in
post-ischemic tissue, upregulate neurotrophic factors, promoting a neuroprotective environment
(Zamanian et al., 2012). While A1 astrocytes have been implicated in multiple neurodegenerative
diseases (Liddelow et al., 2017; Yun et al., 2018), their contribution to glaucoma is only beginning
to be explored.
In the brain and the retina, neurotoxic A1 astrocytes are induced by microglial release of proinflammatory cytokines IL-1α, TNF-α, and C1q (Liddelow et al., 2017). Strong links exist between
these three cytokines and glaucoma. IL1A and TNF polymorphisms are associated with primary
open angle glaucoma (Bozkurt et al., 2011; Fan et al., 2010; Mookherjee et al., 2010; Wang et al.,
2006). TNF-α protein levels are elevated in the vitreous, retina, and optic nerves of glaucomatous
eyes (Williams et al., 2017). In the DBA/2J mouse model of hypertensive glaucoma, C1qa mRNA
levels are associated with disease progression (Stevens et al., 2007), and C1q inhibition is
sufficient to prevent early RGC synapse loss and RGC death (Howell et al., 2011, 2014; Williams
et al., 2016). Multiple publications have also demonstrated C1q upregulation in glaucomatous
human eyes (Reinehr et al., 2016; Stasi et al., 2006). Although IL-1α, TNF-α and C1q have been
independently implicated in glaucoma, it is not known whether they act in concert to induce A1
astrocyte reactivity in glaucomatous retinas.
Glucagon-like peptide 1 is an incretin hormone that regulates blood glucose, weight, and satiety
through its action at the glucagon-like peptide 1 receptor (GLP-1R) in both the systemic circulation
and the central nervous system (Drucker, 2018). NLY01 is a long-acting GLP-1R agonist with an
extended half-life and favorable blood-brain barrier penetration (Yun et al., 2018). In mouse models
of Parkinson’s disease (PD), A1 astrocytes contribute to dopaminergic cell death and poor motor
phenotypes. NLY01 has been shown to reduce microglial production of C1q, TNF-α, and IL-1α,
thereby blocking A1 astrocyte transformation, reducing dopaminergic cell death, and improving
motor symptoms in mouse models of PD (Yun et al., 2018).
Using the microbead-induced ocular hypertension mouse model of glaucoma, we show that
microglia and infiltrating macrophages upregulate C1q, TNF-α, and IL-1α. These three cytokines
are necessary for A1 transformation within the retina. Cytokine upregulation and A1 transformation
persist despite normalization of IOP six weeks post-injection. Genetic deletion of these cytokines
9

prevents A1 astrocyte formation and RGC loss. Finally, NLY01 therapy reduced CD11b+ CD11cand CD11b+ CD11c+ production of C1q, TNF-α, and IL-1α, A1 astrocyte transformation, and RGC
loss in our model. Together, these data demonstrate that GLP-1R activation is capable of reducing
ocular inflammation driven by both CD11b+ CD11c- and CD11b+ CD11c+ cell populations, and
thus preventing A1 astrocyte activation and rescuing RGCs from hypertensive glaucoma. NLY01
has potential clinical use in the treatment of glaucoma and possibly other retinal diseases
characterized by reactive astrogliosis.
Results
Elevated intraocular pressure induces A1 astrocyte reactivity in the retina.
Magnetic microbeads (left eye) or balanced salt solution (BSS, right eye) were injected into the
anterior chamber (AC) of wild-type (WT) and Il1a-/-; Tnf-/-; C1qa-/- triple knockout (TKO) mice.
Intraocular pressure (IOP) was recorded at 1, 2, 3, 5, and 7 days post-injection, and weekly
thereafter. Microbead-injected eyes (Bead) in both WT and TKO animals had elevated intraocular
pressures (eIOPs) beginning at 7 days post-injection compared to BSS-injected eyes (BSS) (Fig.
2-1A). IOPs peaked at 14 days post-injection and remained elevated throughout the 35 days postinjection. There was no difference in IOP between Bead and BSS eyes by the 42nd day postinjection (Fig. 2-1A). Neurosensory retinas were isolated for cell sorting 3, 14, and 42 days postinjection (p.i.) (Fig. S2-1A). Cell-type enrichment for all fractions used in the paper were validated
by qPCR (Fig. S2-1B-C). Astrocytes and Müller cells were isolated using ASCA2+ selection, as
reported previously (Kantzer et al., 2017). By the 14th day post-injection, ACSA2+ cells exhibited
increased levels of pan reactive and A1 astrocyte specific markers (Fig. 2-1B-D), suggesting that
A1 astrocyte transformation occurs early in the disease process. A1 reactivity persisted in
microbead-injected WT animals 42 days post-injection, despite normalization of IOP (Fig. 2-1D).
TKO animals failed to form A1 astrocytes despite eIOP (Fig. 2-1C-D). This is consistent with
previous findings (Guttenplan et al., 2020; Liddelow et al., 2017). Markers of A2 reactivity were
consistently unchanged in WT microbead-injected eyes compared to WT BSS-injected eyes (Fig.
2-1C-D).
Liddelow et al. (2017) demonstrated that complement component 3 (C3) is a marker for A1
astrocytes (Liddelow et al., 2017). We measured C3 mRNA and protein levels in ACSA2+ cells
isolated from both BSS- and microbead- injected WT and TKO retinas 42 days post-injection. C3
mRNA (Fig. 2-1E) and protein (Fig. 2-1F) levels were elevated in WT microbead- injected eyes
compared to both BSS-injected eyes and TKO microbead-injected eyes (Fig. 2-1E-F). These data
suggest that C3 production in ACSA2+ cells, which encompass both astrocytes and Müller cells, is
dependent on IL-1α, TNF-α, and C1q, and that loss of A1 reactivity reduces C3 production.
TNF-α, IL-1α, and C1q contribute to retinal ganglion cell death secondary to eIOP.
To determine whether TNF-α, IL-1α, and C1q transformation of A1 astrocytes play a role in retinal
ganglion cell (RGC) death in the microbead-induced eIOP model of glaucoma, WT, Il1a-/-; Tnf-/double knockout (DKO) mice, C1qa-/- single knockout mice, and Il1a-/-; Tnf-/-; C1qa-/- (TKO) mice
were injected with magnetic microbeads in one eye and BSS in the fellow eye. After 42 days, whole
retina flatmounts were stained for the RGC marker Brn3a (Nadal-Nicolás et al., 2009). Each data
point (Fig. 2-2) represents the RGC count in the microbead-injected eye divided by the RGC count
in the BSS-injected eye of the same mouse, multiplied by 100. There was no difference in RGC
loss observed in DKO mice compared to WT mice. There was a modest improvement in RGC
survival observed in C1qa-/- mice compared to WT mice, consistent with previously published
results (Howell et al., 2011, 2014; Williams et al., 2016). RGC death was reduced in TKO mice
compared to all other genotypes (Fig. 2-2), suggesting that the loss of all three cytokines in
combination provided an additional benefit beyond the loss of either IL-1α and TNF-α or C1q alone.
Early retinal inflammation is driven by CD11b+ CD11c+ cells and persists beyond IOP renormalization.
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To address the time course and source of IL-1α, TNF-α, and C1q production, we injected either
microbeads or BSS into the anterior chamber of WT mice. Neurosensory retinas were isolated 1,
2, 3, 7, 14, 28 and 42 days post-injection and were either used to measure IL-1α, TNF-α, and C1q
protein levels by ELISA or dissociated for cell sorting. IL-1α, TNF-α, and C1q protein levels
increased in line with IOP, rising by day 7 and then plateauing at subsequent time points (Fig. 23A-C). IL-1α, TNF-α, and C1q remained elevated 6 weeks post-injection, despite a return of IOP to
baseline levels (Fig. 2-1A, Fig. 2-3A-C). Microbead-injected eyes that did not have a significant
increase in IOP, observed in approximately 5% of eyes, did not have elevated IL-1α, TNF-α, or C1q
mRNA levels in CD11b+ cells 42 days post-injection (Fig. S2-2A-C). Together these data suggest
that the retinal inflammatory response, initiated by ocular hypertension, can outlast IOP elevation.
Previous studies have implicated CD11b+ cells in the production of IL-1α, TNF-α and C1q
(Liddelow et al., 2017; Yun et al., 2018). Recent work in the DBA/2J mouse model of glaucoma has
further refined our understanding of CD11b+ cell subpopulations. In the DBA/2J mouse model,
early inflammation is driven by CD11b+ CD11c+ cells while CD11b+ CD11c- cells adopt a largely
anti-inflammatory pattern of gene expression (Tribble et al., 2019). We isolated CD11b+ CD11c+
and CD11b+ CD11c- cells (Fig. S2-3A), and measured Tmem119 mRNA levels in both populations
(Fig. S2-3B), a marker of resident microglia (Bennett et al., 2016). We compared the expression of
Il1a, Tnf, and C1qa between CD11b+ CD11c- and CD11b+ CD11c+ cells isolated from microbeadinjected eyes. Both sets of microbead-injected eyes were normalized against BSS-injected eyes.
CD11b+ CD11c+ cells exhibited earlier expression of Il1a, Tnf, and C1qa compared to CD11b+
CD11c- cells (Fig. 2-3D-F). Expression of Il1a, Tnf, and C1qa by CD11b+ CD11c- cells also
increased, but lagged behind those of CD11b+ CD11c+ cells by days to weeks (Fig. 2-3D-F). These
results suggest that CD11b+ CD11c+ provided the primary source of pro-inflammatory signals in
early glaucomatous retinal inflammation following eIOP. In further support of this hypothesis, we
demonstrated that A1 astrocytes were present by 14 days post-injection (Fig. 2-1B-D), when
CD11b+ CD11c- cells did not express all three cytokines necessary for A1 transformation (Fig. 23D-F). Therefore, initial A1 transformation is unlikely to be driven by CD11b+ CD11c- cells in this
model.
NLY01, a GLP-1R agonist, reduces IL-1α, TNF-α, and C1q production by CD11b+ CD11c+ and
CD11b+ CD11c- cells and decreases A1 astrocyte activation during eIOP.
NLY01, a glucagon-like peptide 1 receptor (GLP-1R) agonist, has been shown to modulate
microglial phenotype reducing A1 astrocyte activation in the brain in a GLP-1R-dependent manner
(Yun et al., 2018). We hypothesized that NLY01 therapy would reduce IL-1α, TNF-α, and C1q
production by both microglia and macrophages, thereby decreasing A1 astrocyte conversion
secondary to eIOP. To test the efficacy of NLY01 in our model, we used microbead injections to
induce eIOP (Fig. S2-4). Mice were given twice-weekly subcutaneous injections of either NLY01 at
a dose of 5mg/kg or normal saline solution (NSS). Neurosensory retinas were harvested 14 and
42 days post-injection to evaluate the effects of NLY01 on both the CD11b+ CD11c+ mediated
early response and the CD11b+ CD11c- mediated late response. NLY01 had no effect on
intraocular pressure in microbead- or BSS-injected eyes (Fig. S2-4).
By the 14th day post-injection, NLY01 therapy reduced CD11b+ CD11c- (resident microglia
enriched) upregulation of TNF-α (Fig. 2-4B) without altering basal expressions of IL-1α or C1q (Fig.
2-4A, 2-4C). NLY01 also reduced CD11b+ CD11c+ expression of IL-1α, TNF-α, and C1q (Fig. 24D-F). In the ACSA2+ (astrocyte and Müller cell enriched) fraction, NLY01 also reduced expression
of pan-reactive transcripts, A1-specific transcripts, and C3, consistent with decreased A1 activation
(Fig. 2-4G-H).
By the 42nd day post-injection, NLY01 therapy reduced both CD11b+ CD11c- (resident microglia
enriched) and CD11b+ CD11c- expression of IL-1α, TNF-α, and C1q (Fig. 2-5A-F). NLY01 also
reduced expression of pan reactive transcripts, A1-specific transcripts, and C3 in the ACSA2+
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(astrocyte and Müller cell enriched) fraction (Fig. 2-5G-H), as it had by the 14th day post-injection
(Fig. 2-4G-H).
NLY01 has been shown to reduce the nuclear translocation and phosphorylation of the proinflammatory transcription factor NFκB in a GLP-1R-dependent manner in brain microglia (Yun et
al., 2018). At the 42nd day post-injection, CD11b+ CD11c- and CD11b+ CD11c+ cells isolated from
microbead-injected, NSS-treated eyes exhibited an increase in NFκB protein phosphorylation (Fig.
S2-5A-B). NLY01 treatment decreased phosphorylated NFκB protein levels (Fig. S2-5A-B) and
increased mRNA levels of IκBα (Fig. S2-5C-D), a negative regulator of NFκB and a known target
of GLP-1R (Athauda and Foltynie, 2016). Together these data suggest that NLY01 modulates
microglial/macrophage inflammatory phenotype via GLP-1R.
NLY01 reduces RGC death secondary to eIOP.
To test the efficacy of NLY01 as a potential neuroprotective agent in our model, eIOP was once
again induced through microbead injections of mice treated with either twice-weekly NLY01 at a
dose of 5 mg/kg or NSS. After 42 days, neurosensory retinas were isolated, flat-mounted, and
labeled with RGC markers Brn3a (Fig. 2-6A) and Rbpms (Fig. 2-6B) for RGC counting. Each data
point (Fig. 2-6A-B) represents the RGC count in the microbead-injected eye divided by the RGC
count in the BSS-injected eye of the same mouse, multiplied by 100. NLY01 therapy reduced RGC
death secondary to eIOP, quantified by RBPMS+ and Brn3a+ immunofluorescence and cell
counting (Fig. 2-6A-B).
Discussion
Glaucoma is a neurodegenerative disease with potentially severe visual implications. Therapies to
slow disease progression are currently limited to IOP reduction through both medical and surgical
means. Unfortunately, successful reduction of IOP does not prevent disease progression in a
significant number of patients. New therapies targeting other risk factors for glaucoma are needed
to prevent irreversible vision loss. We examined the role of A1 reactive astrocytes in the microbeadinduced ocular hypertension mouse model of glaucoma. Following induction of ocular
hypertension, IL-1α, TNF-α, and C1q production was initially driven by CD11b+ CD11c+ cells. The
contribution of CD11b+ CD11c- cells to IL-1α, TNF-α, and C1q production was not observed until
weeks to months after ocular injection. Together, these three cytokines triggered the formation of
A1 astrocytes as demonstrated by upregulation of A1-specific transcripts and C3 production in an
ACSA2+ retinal cell population (enriched for astrocytes and Müller cells). Treatment with the GLP1R agonist, NLY01, reduced microglia/macrophage production of IL-1α, TNF-α, and C1q,
decreased A1 astrocyte conversion, and protected against RGC death in this mouse model of
glaucoma.
Recent work by Guttenplan et al. (2020) corroborates several critical findings in this manuscript.
Using both optic nerve crush and microbead injections, they demonstrate that Il1a-/-; Tnf-/-; C1qa/- (TKO) mice exhibit significant reductions in RGC death at rates comparable to our findings.
Further, preserved RGCs are functionally intact under examination by in vivo electrophysiology
(Guttenplan et al., 2020). In combination, these results highlight the neurotoxic role of IL-1α, TNFα, and C1q in RGC death following injury. Guttenplan and colleagues’ finding that rescued RGCs
remain functionally viable lends further credence to inhibition of A1 astrocyte transformation as a
possible therapy for glaucoma.
Transcriptomic data from the DBA/2J mouse model of glaucoma suggest that early inflammation is
driven by CD11b+ CD11c+ cells, while CD11b+ CD11c- cells initially adopt an anti-inflammatory
pattern of gene expression (Tribble et al., 2020a; Williams et al., 2019). Our results support this
finding by demonstrating that CD11b+ CD11c+ cells upregulated IL-1α, TNF-α, and C1q expression
prior to contribution from CD11b+ CD11c- cells. Results suggest that CD11b+ CD11c+ cells are
early contributors to A1 astrocyte formation following IOP elevation (eIOP). Transcriptomic data
from FACS-isolated CD11b+ CD11c+ retinal cells in the DBA/2J mouse model of glaucoma
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demonstrate that this population is enriched for infiltrating macrophages compared to other bloodborne immune cells and resident microglia (Tribble et al., 2020a). It should be noted that the
embryonic origin of the CD11b+ CD11c+ cell population has not been conclusively demonstrated,
and these cells could therefore represent resident retinal microglia that have undergone a state
change, infiltrating macrophages, or a mixture of both. However, macrophage infiltration has been
implicated in the pathogenesis of glaucoma. Specifically, macrophages have been observed in
sections of human glaucomatous retina and optic nerve in both mild and severe cases (Margeta et
al., 2018). Progression of visual field loss in normotensive glaucoma is also associated with
increased systemic levels of macrophage chemoattractant protein-1 (MCP-1), a potent chemotactic
factor for monocytes (Lee et al., 2017). Although the presence of the blood-retina barrier confers a
degree of immune privilege to the retina, disruption of the blood-retina barrier has been observed
in diseases of ocular inflammation (Daruich et al., 2018; Kaur et al., 2008; Kokona et al., 2018;
Vecino et al., 2016). Glaucomatous retinas often exhibit focal bleeds in the nerve fiber layer
surrounding the optic nerve head. These so-called Drance hemorrhages disrupt the blood-retina
barrier and present an opportunity for blood-borne immune cells, such as macrophages, to enter
the retina (Williams et al., 2017). Together these data provide an impetus for future work
characterizing the origin of CD11b+ CD11c+ cells in mouse models of glaucoma as well as the role
of infiltrating macrophages and the integrity of the blood-retina barrier in glaucoma.
Following microbead injections, the time course of IL-1α, TNF-α, and C1q upregulation corresponds
to the trajectory of IOP increase, lending support to eIOP as the initiator of inflammation. Despite a
return to normal IOP, pro-inflammatory cytokines remained upregulated at 6 weeks post-injection,
suggesting that the inflammatory pathway remains active beyond the inciting eIOP. In human
glaucomatous eyes, a reduction in IOP, whether by pharmacological or surgical means, is not
always sufficient to prevent further RGC degeneration. Our data suggest that persistent
inflammation after normalization of IOP may contribute to these refractory cases, presenting a
treatment opportunity for patients who have exhausted therapies rooted in IOP reduction.
A1 astrocytes upregulate complement component 3 (C3) (Liddelow et al., 2017), and C3 inhibitors
were shown to reduce RGC cell death in the DBA/2J mouse model of glaucoma (Bosco et al.,
2018). We demonstrate elevated C3 production following A1 activation and decreased C3
production following NLY01 inhibition in our glaucoma model. Importantly, C3 is not the only source
of toxicity from A1 astrocytes (Liddelow et al., 2017). While C3 inhibition offers some RGC
protection, prevention of A1 astrocyte formation may confer more complete protection against
eIOP.
Within two weeks of microbead injection, pro-inflammatory CD11b+ CD11c+ cells upregulate IL1α, TNF-α and C1q expression, which triggers A1 astrocyte transformation. NLY01 blocks this
pathway and rescues RGCs from eIOP-induced death at 6 weeks post-injection. Previous work
demonstrates that RGC loss does not occur in the microbead model until after 4-6 weeks of
prolonged eIOP (Calkins et al., 2018; Ito et al., 2016; Sappington et al., 2010). This delay between
A1 transformation and RGC death raises the question of whether RGC-autonomous mechanisms
of cell stress must act in concert with the non-cell autonomous mechanism of retinal inflammation
to trigger RGC death. Loss of one of these two pathways, conferred by NLY01 administration in
our study, was sufficient to rescue RGCs. Several observations support this multi-hit hypothesis.
First, in animal models of unilateral glaucoma, where one eye has eIOP and the other eye with
normal IOP is used as an internal control, microglial activation and inflammation can be observed
sans RGC loss in the control optic nerve (Tribble et al., 2020b). Second, neuronal injury, either via
optic nerve crush or eIOP, is a necessary precursor for astrocyte-mediated neuroinflammatory cell
death (Guttenplan et al., 2020). Targeting both RGC-autonomous mechanisms of stress and retinal
inflammation may act in a synergistic fashion to rescue additional RGCs.
Elevated intraocular pressure induces deficits in axon transport along the optic nerve (Lambert et
al., 2017, 2020) and reduction in NaV1.2 protein levels in RGCs (Risner et al., 2020) after 4 weeks
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of ocular hypertension. In contrast, changes in RGC electrical signaling occur earlier after eIOP.
Following just two weeks of eIOP, RGCs exhibit increased electrical responses to preferred stimuli
in both light onset and offset cells. During this same two week period, RGCs exhibit excessive
dendritic pruning (Risner et al., 2018). In both the brain and the retina, dendritic pruning is linked to
the production of C1q, and the subsequent initiation of the classical complement cascade by
CD11b+ cells (Stevens et al., 2007). Our results show that CD11b+ CD11c+ cells, and not CD11b+
CD11c- cells, are responsible for C1q upregulation and possibly downstream dendritic pruning.
NLY01 reduced C1qa expression in CD11b+ CD11c+ cells 2 weeks after IOP elevation, suggesting
that NLY01 may also prevent synaptic pruning in RGCs. A1 astrocytes themselves may also
directly promote aberrant electrical signaling, as in vitro work has shown that A1 astrocytes reduced
the number of synapses, mEPSC frequency, and mEPSC amplitude in cultured RGCs (Liddelow
et al., 2017).
In our study, microbeads were injected into the anterior chamber of one mouse eye while the
contralateral eye was injected with BSS. This paired approach reduced the impact of biological
variability through the use of an internal control. However, recent work has shown that unilateral
induction of eIOP in rats resulted in microglial reactivity throughout the visual pathway, including in
the contralateral, normotensive optic nerve (Tribble et al., 2020b). While most of our experiments
normalized the microbead eye against the normotensive control eye, one exception to this can be
found in Fig. 2-3A-C where absolute protein levels were measured using ELISA. Here,
normotensive eyes showed no upregulation of IL-1α, TNF-α, and C1q proteins, suggesting that if
present, microglial reactivity in the control eye may not result in A1 astrocyte activation in this model
of glaucoma.
NLY01 reduces microglial/macrophage activation and prevents A1 astrocyte formation. NLY01
belongs to a family of glucagon-like peptide 1 receptor (GLP-1R) agonists. NLY01 is a long-acting
GLP-1R agonist that efficiently penetrates the blood-brain barrier (Yun et al., 2018). In mouse
models of Parkinson’s disease, NLY01 concentrations in the brain are higher than in WT animals.
The authors attributed this increase in NLY01 concentration to blood-brain barrier breakdown
present in the Parkinson’s disease mouse models (Yun et al., 2018). Similarly, blood-retina barrier
disruptions in glaucoma (Williams et al., 2017) may serve a therapeutic benefit by providing a
gateway for systemically administered therapeutics to access the retina and the optic nerve. This
further highlights the need to characterize the state of the blood-retina barrier in glaucoma.
Previous work has shown that NLY01’s effects on CD11b+ cells are not limited to reductions in
levels of IL-1α, TNF-α, and C1q. Rather, NLY01 treatment reduces microglia density and relative
IBA1 levels in a mouse model of Parkinson’s disease, suggesting a broader immunosuppressive
effect (Yun et al., 2018). It is therefore possible that the RGC rescue we observed following NLY01
treatment can be partially attributed to a reduction in microglial/macrophage reactivity, and occurs
independent of the drug’s effect on astrocyte phenotype. This is consistent with findings from other
groups demonstrating that reduced CD11b+ cell reactivity protects RGCs from the effects of eIOP
(Williams et al., 2017).
The safety of NLY01 in humans is currently being tested in a clinical trial for Parkinson’s disease.
NLY01 belongs to the GLP-1R class of therapeutic agonists that have been used in the clinic for
over 15 years. During that time, GLP-1R agonists have demonstrated a favorable safety profile in
the long-term treatment of type 2 diabetes mellitus (Aroda, 2018). Diabetes is a known risk factor
in glaucoma (Khan et al., 2016), and GLP-1R agonists’ wide usage in diabetes treatment presents
an opportunity to retrospectively evaluate its effects among patients with coexisting glaucoma in a
large scale observational study. The findings of such a study could provide evidence as to whether
existing GLP-1R agonists affect glaucoma incidence or progression among patients with diabetes.
Glaucoma is a group of diseases with disparate but often interlinking etiologies. Our data highlight
neuroinflammation as a mechanism of glaucomatous damage and demonstrate rescue by NLY01
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through the drug’s ability to decrease retinal inflammation. Current therapies targeting IOP are not
sufficient to prevent vision loss in many glaucoma patients. NLY01, or more broadly the class of
GLP-1R agonists, may be a fruitful avenue for future exploration.
Limitations
RGC degeneration occurs in retrograde fashion, beginning with the retraction of RGC synaptic
terminals in the colliculus, followed by axonal degeneration, with loss of RGC soma constituting a
late step in the degenerative cascade (Buckingham et al., 2008). Our study does not include optic
nerve analysis, and it is important that readers consider alternative explanations for these findings
given this limitation. Rbpms, and to a lesser degree, Brn3a immunolabeling captures most but not
all RGC somas, and it is possible that rescue is more robust than indicated by soma analysis alone.
Conversely, it is possible that RGC counts underestimated RGC death by counting RGC soma that
have yet to degenerate. It is also possible that ablation of A1 astrocytes prolonged expression of
RGC markers in the soma leading to overcounting of RGCs in TKO and NLY01 treated animals. It
should be noted that the rescued RGCs in TKO animals have been shown to be electrically and
functionally intact (Guttenplan et al., 2020). NLY01 treatment decreases IL-1α, TNF-α, and C1q
expression in a similar fashion to TKO, lending credence to the possibility that it rescues RGCs and
preserves their functionality in a similar fashion. Nevertheless, we cannot say definitively that this
is the case following NLY01 treatment until we have evaluated the optic nerve, which we plan to
pursue in future experiments.
Materials & Methods
Mice
All mice were adult (>3 months old), age-, strain- and sex-matched (both male and female mice
were used in each analysis, in all groups). C57BL6/J (WT) mice were obtained from Jackson labs
(Stock Number 000664). Il1a-/-; Tnf-/-, C1qa-/-, and Il1a-/-; Tnf-/-; C1qa-/- (TKO) animals were
generously donated by Ben Barres (Stanford University). All animals were fed ad libitum and
maintained on a 12 h/12 h light/dark cycle in a University of Pennsylvania vivarium. All procedures
were approved by the Institutional Animal Care and Use Committee of the University of
Pennsylvania and complied with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. NLY01 was obtained through a material transfer agreement with Neuraly
(Baltimore, MD). A cohort of mice was treated with either twice-weekly subcutaneous injections of
NLY01 (5 mg kg-1 per injection) or with an equivalent amount of normal saline solution (L21819;
Fisher Scientific).
Anterior Chamber Injection and Intraocular Pressure (IOP) Measurement
The microbead occlusion model was used to induce elevated intraocular pressure as described
previously (Cui et al., 2020). Briefly, mice were anesthetized with intraperitoneal injections of
ketamine (80 mg/kg, Par Pharmaceutical), xylazine (10 mg/kg, Lloyd), and acepromazine (2 mg/kg,
Boehringer Ingelheim Vetmedica). Pupils were dilated with topical 1% tropicamide and 2.5%
phenylephrine (Akorn). Proparacaine anesthetic eye drop at a concentration of 0.5% (Sandoz) were
applied immediately prior to injection. Injection micropipettes were pulled from glass capillaries to
a final diameter of ~ 100 μm and connected to a microsyringe pump. Using a micromanipulator for
positioning, one eye of the mouse was injected with 1.5 μl of sterile 4.5 μm-diameter magnetic
microbeads (1.6 x 106 beads/μL of balanced salt solution; Thermo Fisher Scientific) at a location
< 1 mm central to the limbus, while the other eye was injected with an equivalent volume of
balanced salt solution (Alcon Laboratories). A hand-held magnet was used to target the beads into
the drainage angle. After injection, 0.5% moxifloxacin antibiotic drops (Sandoz) was applied to the
eye. IOP was measured between 8 and 11 a.m. using the Icare TONOLAB tonometer (Icare
TONOVET). An average of three measurements/eye was used.
Retinal cell sorting
ACSA2+, CD11b+ CD11c-, and CD11b+ CD11c+ cells were isolated from adult murine retinas
using the Miltenyi Adult Brain Dissociation Kit (Miltenyi Biotec, 130-107-677) and MACS magnetic
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cell separation system. Briefly, mice were anesthetized, euthanized, and whole neurosensory
retinas were harvested. Retinal tissue was dissociated in manufacturer provided enzyme mixtures
using the gentleMACS dissociator pre-set program: 37C_ABDK_02. Retinal cell suspensions were
passed through a 70 m filter (130-098-462, Miltenyi Biotec) and resuspended in debris removal
solution. Following debris removal, retinal cells were resuspended and incubated in red blood cell
removal solution for 10 mins at 4C. The following isolation steps were performed: (1) positive
selection for ACSA2 (astrocyte and Muller cell enriched, 130-097-678, Miltenyi Biotec), (2) the
remaining negative selection pool was then subjected to positive selection for CD11b (microglia
and macrophage enriched, 130-093-636 Miltenyi Biotec), and (3) the CD11b+ cells were then
selected against CD11c (130-125-835, Miltenyi Biotec). This resulted in three cell populations: (1)
ACSA2+, (2) ACSA2- CD11b+ CD11c-, and (3) ACSA2- CD11b+ CD11c+. Positive and negative
selection steps used MACS magnetic separation LS columns (130-042-401, Miltenyi Biotech)
according to the manufacturer’s protocol. Cells were subsequently used for RNA isolation using
the RNeasy Mini Kit (Qiagen), according to the manufacturer’s protocol.
Quantitative PCR (qPCR)
RNA isolation was performed according to the manufacturer’s protocol (RNeasy kit; Qiagen). cDNA
was synthesized with reverse transcription agents (TaqMan Reverse Transcription Reagents,
Applied Biosystems) according to the manufacturer’s protocol. Realtime qPCR (TaqMan; ABI) was
performed on a sequence detection system (Prism Model 7500; ABI) using the ΔΔCT method,
which provided normalized expression values (normalized against Gapdh). All reactions were
performed in technical triplicates (three qPCR replicates per qPCR probe).
Enzyme-linked immunosorbent assays
ELISA kits were used to measure protein levels of IL-1α (BMS627, Thermofisher Scientific), TNFα (BMS607-3, Thermofisher Scientific), C1q (LS-F55223-1, LifeSpan BioSciences), C3 (ab157711,
Abcam), and phospho- NFκB/total NFκB (Thermofisher Scientific, 50-246-259) according to the
manufacturer’s protocol. Briefly, mouse retinas were collected, in select cases subjected to cell
sorting, and subsequently homogenized in phosphate-buffered saline containing the protease
inhibitor phenylmethylsulfonylﬂuoride (100 lM; EMD, Gibbstown, NJ, USA). Assays were performed
according to the manufacturers’ protocol. Protein levels were determined by comparing the
absorbance produced by the samples with that of a calibration curve. All measurements were
performed in technical triplicate.
Preparation of retinal flatmounts, immunofluorescence, and cell counting
RGC quantification and immunolabeling of flat-mounted retinas were performed as previously
described (Cui et al., 2020). Briefly, eyes were enucleated and fixed in 4% paraformaldehyde.
Retinas were isolated, mounted on glass slides and serially washed with 0.5% Triton X-100 in
phosphate-buffered saline (PBS). Flat-mounted retinas were incubated overnight at 4°C with
antibodies against RNA-binding protein with multiple splicing (RBPMS; EMD Millipore) diluted
1:500 in blocking buffer (2% bovine serum albumin, 2% Triton X-100 in PBS) and brain-specific
homeobox/POU domain protein-3a (Brn3a; Synaptic Systems) diluted 1:1000 in blocking buffer.
The following day, retinas were washed and incubated with Alexa Fluor 488 donkey anti-rabbit IgG
(Invitrogen; 1:1000 in blocking buffer) and Cy3 goat anti-guinea pig IgG (Abcam; 1:500 in blocking
buffer) secondary antibodies for 3 hours at room temperature. After serial washes, flat-mounts were
cover-slipped with Vectashield mounting medium containing DAPI (Vector Laboratories). For each
flat-mount, 12 standardized photomicrographs were taken at 1/6, 3/6, and 5/6 distance from the
center of the retina at 40x magnification by a masked operator. A masked counter quantified the
number of Rbpms- and Brn3a-positive cells in each 40x field (0.069 mm2) using Nikon Elements
analysis software version 4.1 (Nikon Instruments). The average number of cells in the 12
standardized photomicrographs from the microbead-injected eye was normalized to the average
number of cells in the 12 standardized photomicrographs from the BSS-injected eye to calculate
percent survival in the microbead injected eye with eIOP.
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Quantification and Statistical Analysis
All statistical analyses were done using GraphPad Prism 8.0 software. Data was analyzed either
by one-way ANOVA followed by Tukey’s multiple comparisons test for comparing between three
or more samples, or Mann-Whitney U test for comparing between two samples with 95%
confidence without assuming a gaussian distribution. Samples sizes and p-values can be found in
figure legends. Power calculations were performed using G* Power Software V 3.1.9.7 (Faul et al.,
2007). Group sizes were calculated to provide at least 80% power with the following parameters:
probability of type I error (0.05), effect size (0.25).
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Figure 2-1. Elevated intraocular pressure induces A1 astrocyte reactivity in the retina.
C57BL6/J (WT) and Il1a-/-; Tnf-/-; C1qa-/- knockout (TKO) mice were injected either with
microbeads (“Bead”, left eye) into the anterior chamber (“AC”), to increase intraocular pressure
(IOP), or with BSS (right eye).
(A) IOP measurements across the duration of the study in both eyes of WT and TKO animals.
Statistical difference for Bead WT vs BSS WT and Bead TKO vs BSS TKO shown using stars. No
statistical difference was detected between BSS WT and BSS TKO or Bead WT and Bead TKO.
(n=20 eyes per condition per genotype)
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(B-D) qPCR measurements of pan reactive, A1-specific, and A2 specific transcripts from ACSA2+
cells isolated from WT and TKO mice at 3 days (B), 14 days (C), and 42 days (D) post-injection
(“p.i.”). (n=5 eyes per condition per genotype)
(E) qPCR measurements of C3 mRNA levels in ACSA2+ cells 42 days post-injection. (n=5 eyes
per condition per genotype)
(F) ELISA measurements of C3 protein levels in ACSA2+ cells 42 days post-injection. (n=5 eyes
per condition per genotype)
All data presented as mean ± SEM. Mann-Whitney U test, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001 vs. BSS WT. See also Figure S2-1.
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Figure 2-2. TNF-α, IL-1α, and C1q trigger retinal ganglion cell death secondary to eIOP.
(A) C57BL6/J (WT), Il1a-/-; Tnf-/-, C1qa-/- and Il1a-/-; Tnf-/-; C1qa-/- knockout (TKO) mice were
injected either with microbeads (left eye) into the anterior chamber (“AC”), to increase intraocular
pressure (IOP), or with BSS (right eye). At 42 days post-injection mice were euthanized and retinal
flatmounts were stained for the retinal ganglion cell (RGC) marker Brn3a. Cell count for each
microbead-injected eye was normalized against the contralateral BSS-injected eye to determine
percent survival of Brn3a+ cells. n=10 mice per genotype. All data presented as mean ± SEM. One
way ANOVA with Tukey’s multiple comparisons test, *p<0.05, **p<0.01, ***p<0.001.
Representative images are shown on the right. Scale bar = 50μm.
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Figure 2-3. Early retinal inflammation is driven by CD11b+ CD11c+ cells and persists
beyond re-normalization of IOP.
C57BL6/J (WT) mice were injected either with microbeads (“Bead”, left eye) into the anterior
chamber (“AC”), to increase intraocular pressure (IOP), or with BSS (right eye).
(A-C) ELISA measurements of IL-1α (A), TNF-α (B), or C1q (C) protein levels in whole
neurosensory retina at 1, 2, 3, 5, 7, 14, 28, and 42 days post-injection. Statistical test compared
BSS-injected eyes to microbead-injected eyes at the same time points. (n=5 eyes per time point
per condition)
(D-F) CD11b+ CD11c- and CD11b+ CD11c+ cells were isolated from neurosensory retina at 1, 2,
3, 5, 7, 14, 28, and 42 days post-injection. Il1a (D), Tnf (E), and C1qa (F) mRNA levels were
measured by qPCR in both cell populations. qPCR measurements in microbead-injected eyes were
normalized to the contralateral BSS-injected eyes. Statistical tests compared microbead-injected
CD11b+ CD11c+ cells and microbead-injected CD11b+ CD11c- cells at the same time points. (n=5
eyes per time point per condition)
All data presented as mean ± SEM. Mann-Whitney U test, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001. See also Figures S2-1, S2-2, and S2-3.
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Figure 2-4. GLP-1R agonist, NLY01, reduces production of IL-1α, TNF-α and C1q
secondary to eIOP and A1 astrocyte activation on the 14th day post-injection.
C57BL6/J (WT) mice were injected either with microbeads (“Bead”, left eye), to increase intraocular
pressure (IOP), or with BSS (right eye). Following intraocular injections, mice were randomized to
twice-weekly subcutaneous NLY01 (5 mg/kg per injection) or normal saline. Mice were euthanized
14 days post-injection.
(A-F) CD11b+ CD11c- and CD11b+ CD11c+ cells were isolated from neurosensory retina. qPCR
was performed to measure Il1a (A, D), Tnf (B, E) and C1qa (C,F) mRNA levels in each population.
(n=5 eyes per condition)
(G) qPCR measurements of pan reactive, A1-specific and A2 specific transcripts from ACSA2+
cells 14 days post-injection. (n=5 eyes per condition)
(H) qPCR measurement of C3 mRNA levels in ACSA2+ cells. (n=5 eyes per condition)
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All data presented as mean ± SEM. Mann-Whitney U test, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001 relative to BSS NSS. See also Figures S2-1, S2-4, and S2-5.
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Figure 2-5. NLY01 reduces CD11b+ CD11c+ and CD11b+ CD11c- IL-1α, TNF-α and C1q
production and A1 astrocyte activation on the 42nd day post-injection.
C57BL6/J (WT) mice were injected either with microbeads (“Bead”, left eye), to increase intraocular
pressure (IOP), or with BSS (right eye). Following injections, mice were randomized to twice-weekly
subcutaneous NLY01 (5 mg kg-1 per injection) or normal saline. Mice were euthanized 42 days
post-injection.
(A-F) CD11b+ CD11c- and CD11b+ CD11c+ cells were isolated from neurosensory retina. qPCR
was performed to measure Il1a (A, D), Tnf (B, E), and C1qa (C,F) mRNA levels in each population.
(n=5 eyes per condition)
(G) qPCR measurements of pan reactive, A1-specific, and A2 specific transcripts from ACSA2+
cells 42 days post-injection. (n=5 eyes per condition)
(H) qPCR measurement of C3 mRNA levels in ACSA2+ cells. (n=5 eyes per condition)
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All data presented as mean ± SEM. Mann-Whitney U test, **p<0.01, ***p<0.001, ****p<0.0001 vs.
BSS NSS. See also Figures S2-1, S2-4, and S2-5.
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Figure 2-6. NLY01 reduces RGC death secondary to eIOP.
C57BL6/J (WT) mice were injected either with microbeads (“Bead”, left eye), to increase intraocular
pressure (IOP), or with BSS (right eye). Following injection, mice were randomized to twice-weekly
subcutaneous NLY01 (5 mg kg-1 per injection) or normal saline. Mice were euthanized 42 days
post-injection.
(A) Retinal flatmounts were stained for Brn3a. Cell count for each microbead-injected eye was
normalized against the contralateral BSS-injected eye to determine percent survival of Brn3a+
cells. Representative images are shown on the right. Scale bar = 50μm.
(B) Retinal flatmounts were stained for Rbpms. Cell count for each microbead-injected eye was
normalized against the contralateral BSS-injected eye to determine percent survival of Rbpms+
cells. Representative images are shown on the right. Scale bar = 50μm.
n=13 NSS, n=15 NLY01. All data presented as mean ± SEM. Mann-Whitney U test, ***p<0.001,
****p<0.0001 vs. BSS WT. See also Figure S2-4.

26

A
Negative
Selection

NSR

Negative
Selection

ACSA2+

CD11b+

Astrocytes/
Muller Cells

2.0 ACSA2+ Fraction
1.5
1.0

rVEC

Astrocytes
Muller Cells

RPE

Cones

Bipolars

calb1

rbpms

thy1

brna3a

trmp1

arr3

prkca

gnat2

opn1mw

rdh5

opn1sw

vmd2

sag

Rods

rpe65

rho

gnat1

vim

glul

gfap

cralbp

cd68

iba1

Microglia
Macroph.

RGCs HCs

4 CD11b+ Fraction
3
2

rVEC

Microglia
Macroph.

Astrocytes
Muller Cells

RPE

Cones

Bipolars

calb1

rbpms

brna3a

thy1

trmp1

prkca

arr3

gnat2

opn1mw

opn1sw

rdh5

vmd2

sag

Rods

rpe65

rho

gnat1

vim

glul

cralbp

gfap

cd68

iba1

adgre1

cldn5

0

cdh5

1

pecam1

Rel. mRNA (norm. to iba1)

C

adgre1

cdh5

0.0

cldn5

0.5

pecam1

Rel. mRNA (norm. to gfap)

B

Microglia/
Macrophages

RGCs HCs

Supplemental Figure 2-1. Cell sorting paradigm.
C57BL6/J (WT) mice were euthanized and neurosensory retina (“NSR”) was isolated and
dissociated for cell sorting.
(A) Cell isolation protocol using magnetic cell sorting.
(B) qPCR measurements of cell-type specific markers in ACSA2+ cells.
(C) qPCR measurements of cell-type specific markers in CD11b+ cells.
n = 8 eyes. All data presented as mean ± SEM.
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Supplemental Figure 2-2. Microbead-injection alone does not induce CD11b+ production of
Il1a, Tnf, or C1qa.
C57BL6/J (WT) mice were injected either with microbeads (left eye), to increase intraocular
pressure (IOP), or with BSS (right eye). IOP was monitored weekly. Bead eyes that did not have
an IOP increase of 6 mmHg or greater within 2 weeks of injections were termed “non-OHT Bead”
and excluded from eIOP studies.
(A-C) CD11b+ cells were isolated from neurosensory retina 42 days after injection. qPCR was
performed to measure Il1a (A), Tnf (B), and C1qa (C) mRNA levels.
n=5 eyes per condition. All data presented as mean ± SEM.
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Supplemental Figure 2-3. CD11b+ CD11c- vs CD11b+ CD11c+ cell sorting paradigm.
C57BL6/J (WT) mice were euthanized, and neurosensory retina (“NSR”) was isolated and
dissociated for cell sorting.
(A) Cell isolation protocol using magnetic cell sorting.
(B) qPCR measurement of tmem119 mRNA in CD11b+ CD11c+ cells vs. CD11b+ CD11c- cells.
n = 5 eyes. All data presented as mean ± SEM.
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Supplemental Figure 2-4. NLY01 does not affect intraocular pressure.
C57BL6/J (WT) mice were injected either with microbeads (“Bead”, left eye), to increase intraocular
pressure (IOP), or with BSS (right eye). Following intraocular injections, mice were randomized to
twice weekly subcutaneous NLY01 (5 mg kg-1 per injection) or normal saline solution (NSS). IOP
were measured across the duration of the study. Statistical difference for Bead NSS vs BSS NSS
and Bead NLY01 vs BSS NYL01 shown using stars. No statistical difference was detected between
BSS NSS and BSS NLY01 or between Bead NSS and Bead NLY01. All data presented as mean
± SEM. Mann-Whitney U test, ****p<0.0001. (n = 25 eyes per condition per treatment)
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Supplemental Figure 2-5. NLY01 modulates NFκB signaling in CD11b+ CD11c- and CD11b+
CD11c+ cells.
C57BL6/J (WT) mice were injected either with microbeads (“Bead”, left eye), to increase intraocular
pressure (IOP), or with BSS (right eye). Following intraocular injections, mice were randomized to
twice weekly subcutaneous NLY01 (5 mg kg-1 per injection) or normal saline solution (NSS). 42
days post-injection mice were euthanized, neurosensory retina was harvested and sorted as
described in Fig. S2-3A to isolate CD11b+ CD11c- and CD11b+ CD11c+ cells.
(A) ELISA measurements of phospho-NFκB normalized to total NFκB in CD11b+ CD11c- cells.
(B) ELISA measurements of phospho-NFκB normalized to total NFκB in CD11b+ CD11c+ cells.
(C) qPCR measurement of NFKBIA mRNA levels in CD11b+ CD11c- cells.
(D) qPCR measurement of NFKBIA mRNA levels in CD11b+ CD11c+ cells.
All data presented as mean ± SEM. Ordinary one-way ANOVA, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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CHAPTER 3: GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R) AGONIST USE IS
ASSOCIATED WITH REDUCED RISK OF GLAUCOMA
Introduction
Glaucoma is the leading cause of irreversible blindness globally. Primary open angle glaucoma
(POAG) is the most prevalent form and is projected to affect approximately 80 million people
worldwide by 2040.1 In about 60% of cases, POAG is associated with ocular hypertension.2
However, the fraction of POAG associated with elevated intraocular pressure (IOP) varies
significantly across different ethnic and racial groups.3 All available therapies for glaucoma target
IOP reduction through either medical or surgical means. However, disease progression can
continue despite IOP normalization, and aggressive IOP lowering is associated with visionthreatening complications.4,5 New therapies, targeting mechanisms of glaucoma beyond elevated
IOP, are urgently needed to prevent permanent vision loss in patients who have exhausted existing
treatment options.2
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that regulates blood glucose, weight, and
satiety. Agents that increase GLP-1 receptor (GLP-1R) signaling, including GLP-1 analogs and
dipeptidyl peptidase 4 (DPP-IV) inhibitors, have been developed for the treatment of type 2 diabetes
mellitus (DM). GLP-1R agonists first gained FDA-approval in 2005 and include exenatide,
liraglutide, albiglutide, dulaglutide, semaglutide, and lixisenatide. In addition to their effects in the
periphery, GLP-1R agonists cross the blood-brain barrier and exert effects in the central nervous
system, influencing feeding behavior, cellular proliferation, mitochondrial function, and
neuroinflammation.6 GLP-1R agonists are neuroprotective in mouse models of neurodegenerative
diseases including Parkinson’s7 and Alzheimer’s8 disease. A randomized control trial of 45 patients
with Parkinson’s disease found a statistically significant improvement in both motor and non-motor
deficits among subjects treated with exenatide.9 In a randomized control trial targeting Alzheimer’s
disease, liraglutide improved cognitive function.10 Additional trials testing the novel GLP-1R agonist
NLY01 in Parkinson’s (ClinicalTrials.gov, identifier NCT04154072) and Alzheimer’s disease are
ongoing.
Recent work has identified shared mechanisms of neurodegeneration in animal models of
Parkinson’s disease and glaucoma. In both diseases, neuroinflammation driven by glial cell
activation contributes to neuron death.7,11,12 Treatment with NLY01 ameliorated neuroinflammation
in animal models of both diseases to reduce dopaminergic neuron7 or retinal ganglion cell (RGC)11
death. In this study, we used an insurance claims database to examine whether GLP-1R agonist
use impacted the risk for a new glaucoma diagnosis.
Results
After inclusion and exclusion criteria were met, 1,961 new users of GLP-1R agonists (Figure 3-1)
were matched to 4,371 unexposed controls. After matching and inverse proportional treatment
weighting (IPTW), covariates including race, gender, education, income, geographic location,
diagnosis of hypertension, diagnosis of hypercholesterolemia, presence and severity of kidney
disease, history of smoking, mean values of hemoglobin A1c, DCSI, and median days of healthcare
utilization were balanced and comparable between cohorts (standard mean deviation [SMD] <0.1
for all comparisons; see Table 3-1 for baseline and weighted characteristics of the study
population). Age was the only imbalanced covariate (SMD =0.109), with the mean weighted age of
the unexposed cohort (56.1 ±12.72 years [Mean ±SD]) being slightly older than that of the exposed
cohort (54.3 ±19.2 years; see Table 3-1 for all baseline covariates). After IPTW, the unexposed
cohort was 51.4% female, 78.3% White, 12.6% Black, and 7.6% Hispanic, containing 45.9%
patients with diabetic retinopathy, and a mean hemoglobin A1c of 7.92 ±2.36. This compared to
the exposed group after IPTW at 55.0% female, 78.7% White, 11.3% black, and 8.2% Hispanic,
containing 45.7% patients with diabetic retinopathy, and a mean hemoglobin A1c of 7.91 ±3.08.
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During the follow-up period, 58 new diagnoses (1.33%) of glaucoma or glaucoma suspect were
present in unexposed controls compared to 10 new diagnoses (0.51%) of glaucoma or glaucoma
suspect in the GLP-1R agonist cohort. After IPTW of all covariates and the addition of age to the
final multivariable model, Cox regression analysis revealed a 0.54 hazard ratio (HR; 95% CI: 0.350.85, P =0.007; Table 3-2) for incident glaucoma among GLP-1R agonist patients versus
unexposed controls. As expected, each year of increasing age was also a risk factor associated
with incident glaucoma (HR =1.03; 95% CI: 1.01-1.05, P <0.001; Table 3-2).
Discussion
GLP-1R agonists are a common second-line therapy used in the treatment of type II diabetes
mellitus (DM). In a mouse model of ocular hypertension, a novel GLP-1R agonist, NLY01, reduced
retinal ganglion cell (RGC) loss.11 Using a national database, we examined the association between
exposure to GLP-1R agonists and a new diagnosis of glaucoma or glaucoma suspect. Our analysis
identified approximately 6,400 patients who fulfilled our inclusion criteria. Cox regression analysis
showed a significant reduction in hazard for a new diagnosis of glaucoma in patients exposed to a
GLP-1R agonist relative to unexposed patients. These results suggest that, among DM patients,
GLP-1R agonists may reduce the risk for glaucoma.
Preclinical data from a mouse model of ocular hypertension showed that NLY01, a novel GLP-1R
agonist designed to maximize CNS penetration, can reduce retinal inflammation and RGC death.
Although the mechanism of protection has not been definitively determined, evidence suggests that
NLY01 acts on microglia, macrophages, and perhaps astrocytes to reduce local retinal
inflammation and prevent activation of the complement cascade after IOP elevation. Specifically,
GLP-1R agonism reduces microglia/macrophage production of pro-inflammatory signaling
molecules, retinal levels of complement component 3 (C3), and reactive astrocyte formation.11
Together, these immunomodulatory effects may reduce RGC death in ocular hypertension.
Preclinical and randomized clinical trial data suggest that GLP-1R agonists may also be protective
in neurodegenerative diseases of the brain, including Alzheimer’s8 and Parkinson’s7 disease.
Although data on the neuroprotective role of GLP-1R agonists are relatively new, this class of
medication is bolstered by more than 15 years of safety data obtained from their widespread use
in the treatment of DM, making them an attractive therapeutic option for patients suffering from
slowly progressive neurodegenerative diseases who may require decades of therapy to preserve
neurological function of the retina or brain.
Our study focused on DM patients because GLP-1R agonists are FDA-approved to treat DM.
However, it should be noted that multiple studies have shown an association between DM and an
increased risk of POAG.15–17 Despite this association, the mechanistic link between DM and
glaucoma is not well understood, and it is not known whether GLP-1R agonists directly alter
glaucoma risk. Of note, our cohorts were comparable with respect to diabetes severity as
evidenced by the diabetes complications severity index scoreand hemoglobin A1c levels, reducing
the potential confounding effect of DM in this study.
In addition to DM, increasing age is a risk factor for glaucoma.4 In our study, there was a statistically
significant difference in adjusted age between the two cohorts (Table 3-2). However, the difference
in mean age was small (<2 years), and unlikely to account for the observed difference in glaucoma
hazard. In addition, the Cox proportional hazards model used in this study included terms derived
from the weighted propensity scores, GLP-1R agonist exposure, as well as age.
Although our results showed a statistically significant reduction in hazard for a new glaucoma or
glaucoma suspect diagnosis among patients treated with GLP-1R agonists, our analysis identified
only 68 patients across both the unexposed and exposed cohorts who met outcome criteria. This
was largely due to censoring for patients with a gap in active prescription longer than 60 days.
Although this requirement limited the number of patients who met outcome criteria, altering this
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requirement would bias the study towards the null by including more patients not actively taking a
GLP-1R agonist in the exposed cohort. Despite limited numbers, we still found a reduction in hazard
in those treated with GLP-1R agonists, attesting to the robustness of this association.
Further, lack of specific clinical data including visual acuity prevented us from examining whether
GLP-1R agonists reduced the risk of glaucoma progression or improved visual outcomes. Future
work utilizing a larger database containing ocular data, including indicators of glaucoma severity,
would address these limitations to provide a more complete assessment of the potential for GLP1R agonists to provide neuroprotection in glaucoma.
Preclinical data showing GLP-1R agonist-mediated RGC rescue, in combination with our findings,
support further investigation into the use of GLP-1R agonists for glaucoma prevention and
treatment. Given the favorable side-effect profile of GLP-1R agonists, including low incidence of
hypoglycemia18, and the availability of extensive safety data, our results provide a preliminary
impetus for clinicians to preferentially consider GLP-1R agonists in treating patients with DM at
high risk for glaucoma.
Materials & Methods
Data Source
Optum’s de-identified ClinformaticsÔ Data Mart Database was used for this study. This database
contains the medical claims from commercial and Medicare Advantage insurance plans obtained
from a large US insurer. All outpatient medical claims (inclusive of office visits, associated
diagnoses, and laboratory testing) and demographic data for each beneficiary during their
enrollment was accessible. The subset of data available for this study included all patients in the
database from January 1, 2008 to June 30, 2019. The University of Pennsylvania Institutional
Review Board declared this study exempt because it involves anonymized data with removal of
protected health information.
Cohorts
All patients over 18 years old who initiated a new GLP-1R agonist (i.e., exenatide, liraglutide,
albiglutide, dulaglutide, semaglutide, and lixisenatide) were eligible for inclusion in the GLP-1R
cohort. The date the initial prescription was filled was assigned as the index date of each patient.
Exclusions occurred for those with less than two years in the plan prior to the index date, and for
those who did not see an eye care provider at least once prior to the index date. Patients were also
excluded for any history of a glaucoma, glaucoma suspect or ocular hypertension diagnosis, a prior
glaucoma procedure/surgery, or an active glaucoma medication prescription in the 6 months prior
to the index date. See Supplemental Table 3-1 for all glaucoma-related codes used in this study.
An unexposed comparison cohort was created from patients who initiated a new oral diabetic
medication during their time in the insurance plan. GLP-1R agonist patients were matched 1:3 on
age, gender, race, and year of index date to the unexposed cohort. For additional equalization,
cohorts were also matched on the number of active diabetic medications at the time of the index
date. Active medication was defined as the number of active prescriptions within 45 days of the
index date (i.e., if a patient initiating a GLP-1R agonist was already using 2 other diabetic
medications, then the matching unexposed patient was also required to be initiating a 3rd nonGLP-1R agonist class of diabetic medication). Matched unexposed patients were also required to
meet all inclusion and exclusion criteria outlined above.
Outcomes and Covariates
The primary outcome of interest was an ICD-9 or 10 incident diagnosis code for primary open angle
glaucoma, glaucoma suspect, or low tension glaucoma at any time after the index date. Covariates
assessed at the time of the index date were age, sex, race, geographic location, yearly income,
and education level. Systemic health states were created for hypertension, hypercholesterolemia,
kidney disease (e.g., none, chronic, or end stage renal disease), and the diabetes complications
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severity index (DCSI). The DCSI is a validated metric that is calculated using diagnosis codes from
six categories of diabetic complications.13 Lab values were also assessed for the level of
hemoglobin A1c. Health care utilization in the year prior to the index date was accounted for by
counting every distinct day with at least one claim for an office visit, and served as a proxy for
overall health status. While smoking is not often directly coded for in administrative datasets, we
used a combination of smoking diagnosis codes, use of antismoking drugs, and Current Procedural
Terminology (CPT) codes for smoking cessation counseling as proxies. This method has previously
found smoking rates in administrative databases to be 10-11%, similar to that reported in the
general population.14 To account for differences in these baseline covariates between the GLP-1R
agonist and unexposed cohorts, inverse probability of treatment weighting (IPTW) using the
estimated propensity scores from all covariates was performed in all subsequent analyses.
Statistical Analysis
Descriptive statistics were used to analyze the data, with continuous variables reported using mean
and standard deviation and categorical variables using frequency and percentage. A multivariable
Cox proportional hazard regression was performed to determine the association between hazard
of developing glaucoma and GLP-1R agonist exposure. Patients were censored if any of the
following exclusion criteria occurred after the index date: initiation of the comparison cohort of
medication, a gap of >60 days or more in active prescription for the cohort medication, a new
diagnosis for a different form of glaucoma not included as the outcome, the patient exited from the
insurance plan, or the end of observation was reached. All data analyses were performed using
SAS software (version 9.4; SAS Institute Inc., Cary NC).
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Figures & Tables
Figure 3-1. Flowchart showing inclusion/exclusion criteria for study patients.

4,914,051 patients on ≥1 antidiabetic medication

361,501 patients taking a
GLP-1R agonist

129,796 patients enrolled in
insurance ≥2 years prior to
index date

3,128 patients with ≥1 visit
with eye care provider prior to
index date

3,126 patients <18 years old
at index date

2,386 patients without
previous glaucoma diagnosis,
surgeries, or prescriptions

1,961 patients matched
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Table 3-1. Baseline characteristics.
Variable
Non-user
(n=4371)
Race
Asian
Black
Hispanic
White
Gender (female)
Age
Education
<12th Grade
High School
Diploma
<bachelor’s
degree
Bachelor’s
degree+
Unknown
Income
Unknown
<$40K
$40K-$49K
$50K-$59K
$60K-$74K
$75K-$99K
$100K+
Geographic
Division
Mountain
Northeast
Pacific
South Atlantic
Southern
Midwest
Unknown
Upper Midwest
Diabetic
retinopathy
Hypertension
Hypercholesterol
emia
Kidney Disease
No
CKD
ESRD
Smoking
HbA1c level
(mean(SD))

GLP-1R agonist User
(n=1961)

Unweighted

Weighted

Unweighted

Weighted

69 (1.58%)
542 (12.40%)
330 (7.55%)
3430 (78.47%)
2271 (51.96%)
55.63 (10.59)

1.55%
12.61%
7.57%
78.27%
51.41%
56.09
(12.72)

33 (1.68%)
234 (11.93%)
157 (8.01%)
1537 (78.38%)
1028 (52.42%)
55.43 (10.43)

1.72%
11.31%
8.23%
78.74%
55.04%
54.31
(19.19)

14 (0.32%)
1321 (30.22%)

0.30%
30.22%

5 (0.25%)
589 (30.04%)

0.30%
30.34%

2380 (54.45%)

54.56%

1079 (55.02%)

54.18%

638 (14.60%)

14.61%

286 (14.58%)

14.93%

18 (0.41%)

0.32%

2 (0.10%)

0.25%

533 (12.19%)
661 (15.12%)
260 (5.95%)
336 (7.69%)
481 (11.00%)
708 (16.20%)
1392 (31.85%)

12.28%
15.23%
5.83%
7.38%
10.52%
16.18%
32.59%

246 (12.54%)
296 (15.09%)
108 (5.51%)
132 (6.73%)
189 (9.64%)
322 (16.42%)
668 (34.06%)

12.26%
15.62%
5.98%
7.11%
10.48%
16.06%
32.49%

Standard
mean
difference
0.047

0.073
-0.109
0.016

0.016

0.039
326 (7.46%)
314 (7.18%)
254 (5.81%)
1491 (34.11%)
695 (15.90%)

7.51%
6.75%
5.41%
34.23%
17.54%

148 (7.55%)
113 (5.76%)
88 (4.49%)
677 (34.52%)
405 (20.65%)

7.77%
6.72%
5.62%
33.98%
17.70%

4 (0.09%)
1287 (29.44%)
1817 (41.57%)

0.06%
28.50%
45.87%

0 (0.00%)
530 (27.03%)
1094 (55.79%)

0.00%
28.21%
45.74%

-0.003

3507 (80.23%)
3735 (85.45%)

82.61%
87.29%

1722 (87.81%)
1792 (91.38%)

82.23%
87.05%

-0.010
-0.007

3105 (71.04%)
1188 (27.18%)
78 (1.78%)
1061 (24.27%)
7.82 (1.90)

66.49%
31.30%
2.21%
24.90%
7.92
(2.36)

1104 (56.30%)
798 (40.69%)
59 (3.01%)
510 (26.01%)
8.12 (1.80)

66.82%
30.94%
2.24%
24.94%
7.91 (3.08)

0.008
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0.001
-0.006

# of days of
7.39 (6.26)
8.11
9.28 (6.70)
8.22
0.012
health care
(8.64)
(10.50)
usage
(mean(SD))
DCSI
1.66 (1.98)
1.81
2.12 (2.16)
1.83 (3.62) 0.004
(Mean(SD))
(2.51)
# of active DM
1.66 (0.74)
1.89 (0.82)
med classes
(mean(SD))
Time prior to
censoring/events
Mean (SD)
266.5 (299.8)
143.9 (195.1)
Median (Q1151 (91-326)
84 (28-168)
Q3)
Number of
events (new
diagnosis of
glaucoma or
glaucoma
suspect)
No event
4313 (98.67%) 98.65%
1951 (99.49%)
99.60%
Had an event
58 (1.33%)
1.35%
10 (0.51%)
0.40%
Abbreviations: CKD: Chronic Kidney Disease; ESRD: End-Stage Renal Disease; HbA1c:
Hemoglobin A1c; DCSI: Diabetes Complications Severity Index; DM: Diabetes Mellitus.
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Table 3-2. Multivariable Cox regression analysis with inverse probability of treatment weighting.
Variable
Category
Hazard Ratio (95% CI)
P-value
GLP-1R agonist
0.007
User
0.54 (0.35, 0.85)
Non-user
Ref.
Age
1.03 (1.01, 1.05)
<0.001
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CHAPTER 4: MALADAPTIVE ACTIVATION OF NUTRITIONAL IMMUNITY IN
PARKINSON’S DISEASE
Introduction
Iron is essential for life1–3. Under physiological conditions, iron can accept and donate electrons,
serving as a cofactor in fundamental biochemical processes such as oxidative phosphorylation and
DNA repair4. However, iron’s very source of utility is also its source of toxicity. By toggling between
oxidation states, ferrous iron can react with hydrogen peroxide to form reactive oxygen species
(ROS)5–7. These ROS modify intracellular macromolecules such as DNA, lipids, and proteins,
leading to cell dysfunction and death8–10. Given iron’s essential role as an enzymatic cofactor for
both eukaryotic and prokaryotic organisms, control of iron is a critical component of nutritional
immunity, the branch of the innate immune system which regulates the availability of essential
elements to pathogens11,12. As part of the immune response to extracellular microbes, eukaryotic
cells sequester iron by increasing iron import and decreasing iron export to starve extracellular
pathogens of the iron necessary for their survival13–15. We term this pathway the cellular iron
sequestration response (CISR).
Chronic neuroinflammation contributes to multiple neurodegenerative diseases, including
Alzheimer’s disease16, Parkinson’s disease17, and others18–20. Previous work has shown that many
of these same diseases are also associated with iron dyshomeostasis and cellular iron
accumulation21–28. We hypothesized that neuroinflammation activates a local CISR, triggering brain
iron dyshomeostasis and cellular iron accumulation relevant to a broad spectrum of
neurodegenerative diseases.
Results
Trans-Interleukin-6 Signaling Drives Neuronal Iron Accumulation
Interleukin-6 (IL-6) affects iron homeostasis, especially in anemia of chronic inflammation and
sepsis29, leading to the hypothesis that IL-6 may contribute to a CNS CISR. To test this, wild-type
(WT) and Il6-/- (IL6 KO) mice were injected intraperitoneally with lipopolysaccharide (LPS), an
established inducer of neuroinflammation30 or normal saline solution (NSS). One day after LPS
administration mice were euthanized and whole cortex was dissected, dissociated into a single cell
suspension, and sorted into individual cell populations (Fig. S4-1). In response to LPS injection, IL6 protein levels were elevated in whole neocortex (Fig. S4-2A). Cell populations enriched for
microglia/macrophages, astrocytes, and neurons (Fig. S4-1) upregulated interleukin-6 (IL-6) mRNA
(Fig. S4-2B). Cortical neurons isolated from LPS injected mice exhibited an IL-6-dependent
elevation in intracellular iron (Fig. 4-1A). Treatment with FDA-approved iron chelator deferiprone
(DFP) prevented LPS-induced neuronal iron accumulation (Fig. 4-1B). Iron is a known contributor
to oxidative stress7. To determine if LPS-mediated, IL-6-dependent iron accumulation in neurons
resulted in oxidative stress, we measured levels of Hmox1 mRNA (Fig. 4-1C, D) and
malondialdehyde (MDA), an oxidized lipid product (Fig. 4-1E, F). In response to LPS administration,
neuronal Hmox1 mRNA levels and MDA levels increased in an IL-6 and iron-dependent manner
(Fig. 4-1C-F).
IL-6 is known to regulate the expression of multiple iron transport genes, including Zip14, a ferrous
iron importer31, and Hamp, which encodes the peptide hormone hepcidin that inhibits cellular iron
export29. To determine whether the IL-6 dependent neuronal CISR is mediated by Hamp, Zip14 or
other iron transport genes, we measured the expression of 24 genes known to regulate iron
homeostasis in cortical neurons from both LPS- and NSS-injected WT and IL6 KO mice. Of the 24
genes we tested, 6 were differentially expressed in response to LPS administration in an IL-6dependent manner; they include iron import associated proteins Zip14, Tf, Tfrc, Dmt1, intracellular
iron storage proteins Ftl, Fth, and the negative regulator of iron export, Hamp (Fig. 4-1G).
Consistent with this, transgenic mice that constitutively overexpress IL-6 in the brain exhibit cortical
neuronal iron accumulation (Fig. S4-3A) and upregulation of Zip14, Tfrc, Dmt1, Ftl, Fth and Hamp
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(Fig. S4-3B), the same 6 genes upregulated in an IL-6-dependent manner in the LPS-injected mice
(Fig. 4-1G).
The biological effects of IL-6 can be mediated by a cis- or trans-signaling pathway. The cis-signaling
pathway is initiated by membrane-bound IL-6R. IL-6 signaling can also occur in cells which do not
express IL-6R via the trans-signaling pathway32. Here, soluble IL-6R binds IL-6 extracellularly. The
resulting complex can interact with membrane-bound gp130 to initiate intracellular signal
transduction. Gp130 is widely expressed in multiple cell types including neurons33. To determine if
cis- or trans-IL-6 signaling is sufficient to induce the observed IL-6-dependent changes in neuronal
iron homeostasis we treated cultured cortical neurons with either transferrin-bound Fe3+ or labile
Fe2+ and IL-6 or hyper IL-6 (HIL-6, a conjugated protein linking IL-6 and soluble IL-6R that activates
trans-signaling). HIL-6, but not IL-6, was sufficient to induce neuronal iron accumulation in the
presence of labile ferrous but not ferric iron (Fig. S4-3C). This iron accumulation induced neuronal
MDA formation and death (Fig. S4-3D-E).
Based on data derived from the LPS-injected and IL-6 transgenic mice, as well as primary neuron
cultures, we defined the CNS CISR as the accumulation of intracellular iron, elevated markers of
oxidative stress and increased expression of 3 genes associated with iron import (Zip14, Tfrc,
Dmt1) and 1 gene associated with regulation of iron export (Hamp). Although the CISR was defined
in a cell population enriched for neurons, we also observed IL-6-dependent, as well as IL-6independent, changes in the expression of Zip14, Tfrc, Dmt1, Ftl, Fth, and Hamp in
microglia/macrophage-enriched cell populations (Fig. S4-4A) and astrocyte-enriched cell
populations (Fig. S4-4B), suggesting that LPS-induced CISR may occur across multiple cell types
in the brain.
The Cellular Iron Sequestration Response Contributes to PD-like Neurodegeneration In Vivo
Co-incident inflammation and iron accumulation are observed in multiple neurodegenerative
diseases34–37. Among them, Parkinson’s disease (PD), is notable for its rich literature on the
potential pathogenic role of iron38–40. We hypothesized that the neuronal CISR mechanism
identified in LPS-injected mice may also contribute to iron dyshomeostasis in PD. To test this
hypothesis WT and IL-6 KO mice underwent intrastriatal injection of α-synuclein preformed fibrils
(α-syn PFF), whose prion-like spread contributes to sporadic forms of PD41, or control PBS at 2
months of age. Six months after α-syn PFF injection, mice were perfused and euthanized. IL-6
protein levels were elevated in substantia nigra isolated from α-syn PFF-injected mice (Fig. S45A). Individual cell populations were isolated. Astrocytes and microglia/macrophages from α-syn
PFF-injected brains exhibited elevated levels of Il6 mRNA (Fig. S4-5B). Cortical neurons from αsyn PFF-injected brains exhibited multiple IL-6-dependent changes: iron accumulation (Fig. 4-2A),
upregulation of Hmox1 (Fig. 4-2B), increased MDA (Fig. 4-2C) and elevations in Zip14, Tfrc, Dmt1,
Ftl, Fth and Hamp mRNAs (Fig. 4-2D). Zip14, Tfrc, Dmt1, Ftl, Fth and Hamp mRNAs were also
elevated in neurons isolated from the cortex of hA53T transgenic mice, a model of hereditary PD
(Fig. S4-6A), and neurons isolated from the substantia nigra of 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP)-injected mice, a model of toxin-mediated PD (Fig. S4-6B). In the α-syn
PFF model, we also measured CISR gene expression changes in glia. In both the
microglia/macrophage-enriched fraction (Fig. S4-7A) and astrocyte-enriched fraction (Fig. S4-7B),
changes in CISR genes were partially IL-6-dependent suggesting that another cytokine or signaling
molecule may also contribute to CISR activation in glia.
α-syn PFF injection in WT mice leads to a significant loss of tyrosine hydroxylase (TH) and Nissl
positive neurons in substantia nigra pars compacta (SNpc) (Fig. 4-2E), and decreased levels of TH
and dopamine transporter (DAT) protein (Fig. 4-2F). Corresponding motor deficits characterized by
the pole test (Fig. 4-2G, H) and limb grip strength (Fig. 4-2I, J), serve as measures of dopaminergic
neuron function. Compared to WT mice, IL-6 KO mice injected with α-syn PFF exhibited less
dopaminergic neurodegeneration (Fig. 4-2E), higher levels of TH and DAT protein (Fig. 4-2F), and
partial, but significant, rescue of motor function (Fig. 4-2G-J).
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The direct effect of reducing iron levels on neurodegeneration was evaluated with deferiprone in
the α-syn PFF model. We administered deferiprone through daily drinking water beginning one
week after the intrastriatal injection of α-syn PFF and continuing until euthanasia 6 months after
injection. Deferiprone ameliorated dopaminergic neuron loss (Fig. 4-3A), reduction in TH and DAT
levels (Fig. 4-3B), and behavioral deficits (Fig. 4-3C-F).
Hallmarks of the CISR Are Observed in PD Substantia Nigra
We measured expression of CISR genes in substantia nigra tissue from both α-syn PFF-injected
and hA53T transgenic mice to determine if the CISR gene expression signal was detectable in bulk
substantia nigra and neocortex respectively. In both mouse models of PD, the CISR gene
expression profile was observed in bulk brain tissue (Fig. S4-8A, B). To determine whether IL-6
dependent CISR may occur in human PD, we measured mRNA and protein levels of CISR genes
in the SN of postmortem brains from patients with PD and controls (subjects described in
supplemental table 4-1). Gene expression analysis from human PD substantia nigra tissue
exhibited increases in ZIP14, TFRC, DMT1 and HAMP mRNA levels (Fig. 4-4A-D), consistent with
the CISR we identified in mice. Furthermore, these mRNA changes translated to increased protein
levels for ZIP14, DMT1, and TfR1 (Fig. 4-4E-G). The increase in HAMP mRNA correlated with a
decrease in FPN protein levels, as the HAMP gene product, hepcidin, triggers degradation of FPN
(Fig. 4-4H).
Discussion
The data presented herein demonstrate that neuroinflammation can activate a local cellular iron
sequestration response, or CISR, leading to neuronal oxidative stress. While such a response may
be adaptive during cases of CNS infection, chronic inflammation, observed in multiple
neurodegenerative diseases, may lead to prolonged maladaptive activation of the CISR triggering
neuronal oxidative stress and neurodegeneration. Using mouse models of PD, we show that
pathologic α-synuclein induces CISR in neurons leading to dopaminergic cell death and
neurobehavioral deficits. Targeting the CISR pathway through genetic ablation or small-molecule
therapies, was sufficient to partially rescue these deficits. The presence of the transcriptional CISR
signature in postmortem PD brains suggest that this mechanism of iron accumulation, observed in
three etiologically distinct models of PD, occurs in Parkinson’s disease itself.
During periods of systemic inflammation, including chronic disease and sepsis, a coordinated
response by the liver and immune system starves the blood of iron necessary for bacterial cell
replication. This reduction in circulating iron reduces bone marrow iron concentrations, preventing
the formation of hemoglobin and triggering anemia of chronic disease/anemia of inflammation42.
This systemic iron sequestration response is driven by interleukins and many of the same iron
transport proteins studied herein, including hepcidin (HAMP), transferrin receptor (TFRC), and
Zip14 (SLC39A14). In neurons, as in the systemic CISR, IL-6 mediates a coordinated upregulation
of iron import genes (Zip14, Dmt1, Tfrc) and iron regulatory hormone hepcidin, which triggers the
internalization and degradation of the only known mammalian iron exporter, ferroportin (Fpn).
Together these pathways upregulate iron import and down regulate iron export, sequestering iron
inside neurons and leading to increased risk of oxidative stress and cell death.
The effect of both IL6 genetic deletion and iron chelation therapy on the PFF-injected mice were
statistically significant, albeit partial. Several factors could explain the partial protection, including
baseline variability in behavioral measurements. Further, the data presented herein indicate that
CISR in glia is not entirely dependent on IL-6, suggesting that it may be beneficial to block several
CISR-inducers simultaneously. It is also likely that the neuronal CISR is one of several pathways
that triggers neurodegeneration in this mouse model. Therefore, iron-targeted therapy may best
serve patients alongside other disease modifying therapies. NLY01, a molecule being tested in
phase II clinical trials for Parkinson’s disease, showed significant reductions in PFF-mediated
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neuron death in murine models. In fact, NLY01 reduces IL-6 protein levels in PFF brains,
suggesting that NLY01 may reduce IL-6 dependent neuronal CISR43.
Based on these data, strategies aimed at interfering with IL-6 production, IL-6 activity or iron
accumulation may offer therapeutic benefit in PD. A phase I/II human clinical trial of deferiprone for
PD showed a hint of efficacy44–46, which together with these mechanistic data, justify a larger trial.
Intriguingly, PD is not the only neurodegenerative disease associated with chronic inflammation
and iron accumulation34–37. Future interrogation of the CISR in diseases associated with chronic
neuroinflammation is warranted and may provide an opportunity for therapeutics aimed at
devastating conditions including Alzheimer’s disease, amyotrophic lateral sclerosis, and agerelated macular degeneration.
Methods & Materials
Animals
C57BL6/J WT (Jackson Labs, 000664) and IL-6 KO (Jackson Labs, 002650) mice were obtained
from the Jackson Laboratories (Bar Harbor, ME). GFAP-IL6 transgenic mice were obtained from
Scripps Research Institute via material transfer agreement 47. For acute neuroinflammatory injury,
12 week old C57BL6/J WT mice from Jackson Labs (000664) were given a single intraperitoneal
injection of either endotoxin-free PBS or lipopolysaccharide from E. coli O55:B55 (Sigma Aldrich,
L2880) dissolved in normal saline solution and diluted into endotoxin-free PBS at a concentration
of 5mg/kg. For toxin-induced dopaminergic neurodegeneration, 12 week old C57BL6/J WT mice
from Jackson Labs (000664) were given a single subcutaenous injection of either 20mg/kg MPTPHCl (Sigma Aldrich, M0896) or normal saline. PBS- and α-syn PFF-injected mice were treated with
0.5 mg/mL deferiprone (ApoPharma, Toronto, Canada) dissolved in their drinking water starting 1
week after injection and continuing until sacrifice. Previous data have shown that this dose is
sufficient to reduce iron-induced neurodegeneration in mice 48. All housing, breeding, and
procedures were performed according to the NIH Guide for the Care and Use of Experimental
Animals, ARVO standards for the use of animals and approved by either the Johns Hopkins
University Animal Care and Use Committee or the University of Pennsylvania Animal Care and Use
Committee.
Dissociation of Cortex or Substantia Nigra
Mice were perfused with 0.9% NaCl solution (Braun Medical Inc., Cat # L8000). Neocortex or
substantia nigra were dissected, washed with D-PBS (Invitrogen, Cat # 14040117) and minced into
2-4mm pieces. The Miltenyi Biotec Adult Brain Dissociation Kit (Cat # 130-107-677) was used to
generate a single cell suspension. Briefly, minced brain tissue was added to a pre-warmed enzyme
mixture before being incubated with agitation at 37C using the gentleMACS Octo Dissociator with
Heaters (Miltenyi Biotec, Cat #130-096-427) on the 37C_NTDK_1 dissociation program. Following
dissociation, the Debris Removal Solution was used to eliminate cellular and extracellular matrix
debris before the cell suspension was applied to a moistened 70 micron filter (Miltenyi Biotec, Cat
# 130-098-462). After filtering the suspension was centrifuged at 300xg for 10 minutes at room
temperature, the supernatant was aspirated and cells were resuspended in D-PBS. Using a
hemocytometer the number of cells in the suspension was counted.
Cell Labeling & Sorting
The cell sorting scheme we employed is shown graphically in Fig. S4-1A. All cell sorting steps relied
on Miltenyi Biotec Microbead Kits: Anti-ACSA-2 Microbead (Cat # 130-097-678), Anti-CD11b
Microbead (Cat # 130-126-725), Anti-O4 Microbead (Cat # 130-094-543), and Anti-CD31
Microbead (Cat # 130-097-418). Briefly, at each selection step Fc receptors were blocked with an
FcR Blocking Reagent. Cells were then incubated with a magnetically labeled antibody targeting
the epitope of interest (ACSA-2, CD11b, O4, CD31). The cell suspension was passed through an
MS column (Miltenyi Biotec, Cat # 130-042-201) in a magnetic field so that magentically labeled
cells remained in the column while unlabeled cells passed through the column. This process was
repeated twice over two separate MS columns to maximize purity of the isolated population.
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Positively and negatively selected cell populations were discarded or saved for further use as
described in Fig. S4-1A.
Inductively-Coupled Plasma Mass Spectrometry
Samples were analyzed for metals using a Nexion 300D (Perkin Elmer, Shelton, CT). The analytical
standards were purchased from SCP (Champlain, NY) and trace metal grade nitric acid was
purchased from Fisher Scientific (Pittsburgh, PA). All dilutions will be done using in-house
deionized water (≥18 MΩ) obtained from a water purification system (EMD Millipore, Billerica, MA).
The dried bovine liver sample (1577 C) used as reference material was obtained from NIST
(National Institute of Standards and Technology, Gaithersburg, MD). The tissue samples were dried
overnight in an oven set at 70°C and then weighed into Teflon PFA vials (Savillex, Minnetonka,
MN). The dried tissue samples were then digested overnight with 20 times the quantity
(weight/volume) of 70% nitric acid at 70°C. A 0.1 mL portion of the digested tissue sample was
then mixed with 0.05 mL of 2 ppm internal standard containing Ge (germanium), In (indium), Tb
(terbium), and Y (yttrium) and the mixture was diluted with deionized water to a final volume of 5
mL for analysis. The concentration of each metal in the submitted sample was measured using a
calibration curve of aqueous standards prepared at four different concentrations of each metal. The
accuracy of the results was monitored by analyzing reference material (NIST 1577C) with known
values of metals of interest with each batch of samples. Total iron measurements for each sample
were normalized by the number of cells in the sample.
Quantitative PCR
RNA isolation was performed according to the manufacturer’s protocol (RNeasy kit; Qiagen). cDNA
was synthesized with reverse transcription agents (TaqMan Reverse Transcription Reagents,
Applied Biosystems) according to the manufacturer’s protocol. Gene expression was analyzed
using a commercial sequence detection system (ABI Prism 7500, Applied Biosystems). All
reactions were performed in technical triplicate. Probes were obtained from ThermoFisher
Scientific.
Tissue lysate preparation and western blot analysis
Mouse brain tissues or human postmortem brain (Table S4-1) were homogenized and prepared in
lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 % Triton x-100, 0.5 % SDS,
0.5 % sodium-deoxycholate, phosphatase inhibitor mixture I and II (Sigma-Aldrich, St. Louis, MO),
and complete protease inhibitor mixture (Roche, Indianapolis, IN)], using a Diax 900 homogenizer
(Sigma-Aldrich). After incubation at 4 °C for 30 min for complete lysis, the samples were then
centrifuged at 15,000 x g for 20 min and the supernatants were used for further analysis. Protein
concentration were quantified using the BCA assay (Pierce, Rockford, IL). The samples were mixed
with 4x Laemmli sample buffer (Bio-Rad, Hercules, CA) and then separated using SDSpolyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were blocked
with 5 % non-fat milk in TBS-T (Tris-buffered saline with 0.1 % Tween-20) for 1 h, probed using
primary antibodies (Table S4-2) and incubated with appropriate HRP-conjugated secondary
antibodies (Cell signaling, Danvers, MA). The bands were visualized by ECL substrate.
Malondialdehyde (MDA) Quantification
MDA competitive ELISA kit from Abcam (ab238537) was used accounting to manufacturer’s
protocol. Briefly, isolated neurons were lysed, and cell lysates were placed in an MDA conjugate
coated plate. After incubation the wells of the plate were labeled with an HRP-conjugate secondary
antibody. Absorbance at 450nm was quantified and compared to a standard curve to quantify the
amount of MDA present in the experimental samples. All measurements shown herein are the
average of two technical replicates.
Primary Cortical Neuron Cultures
Neuronal cultures were prepared as described previously. 43 Briefly, C57BL6/J mice (Jackson Labs,
Stock No. 000664) were bred to generate E15.5 pups. Cortical neurons were harvested from the
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E15.5 pups (both sexes) and cultured in neurobasal media (Gibco, 21103049) supplemented with
B-27 (Gibco, 17504044), 0.5 mM L-glutamine (Thermo Fisher Scientific, 21051024), penicillin and
streptomycin (Thermo Fisher Scientific, 15140122) on tissue culture plates coated with poly-Llysine. Media was changed every 3 days and cells were used on day 10-14 after plating. Neurons
were treated for 24 hours with 2 µM iron in one of two forms, either transferrin bound Fe3+ or Fe2+
ascorbate, alone or in the presence of 100pg/mL recombinant IL-6 (SRP3330, Sigma Aldrich) or
an equimolar concentration of hyper-IL-6 (9038-SR-025, R&D Systems). After 24 hours, cells were
processed for downstream applications including iCP-MS, MDA ELISA, and cell viability assay.
Cell Viability Analysis
Cell viability was tested using trypan blue live cell counting. Cultured cortical neurons were treated
as described in the text and then dissociated into a single cell suspension using trypsin. A 1:1
mixture of trypan blue solution and cell suspension was placed in the live cell counter (Countess,
Invitrogen) and the number of living and dead cells was measured.
Alpha Synuclein Preformed Fibril (PFF) Preparation
Recombinant mouse α-syn protein were purified 49 or purchased (Novus Biologicals, NBP2-61595)
and then diluted into PBS at a concentration of 5mg/mL. α-syn PFF were prepared with heated
magnetic stirring (1000 rpm, 37° C) in PBS for 7-days. The resulting α-syn aggregates were diluted
to 0.1mg/mL with PBS, sonicated for 30 seconds (0.5 second pulse on/off) at 10% amplitude.
Formation of PFF was validated by the ability of the PFF to induce phospho-serine 129 α-synuclein
(p-α-synser129) in cultured primary neurons. Prepared α-syn PFFs were used immediately or stored
at -80˚ C until used.
Stereotaxic injection of α-syn PFF
Two to 3-month-old WT and IL-6-1 KO mice were deeply anesthetized with a mixture of
ketamine (100 mg/kg) and xylazine (10 mg/kg). PBS or α-syn PFF (5 μg) was unilaterally injected
into striatum (2 μl per hemisphere at 0.4 μl/min) with the following coordinates: anteroposterior (AP)
= +0.2 mm, mediolateral (ML) = + 2.0 mm, dorsoventral (DV) = +2.8 mm from bregma. After the
injection, the needle was maintained for an additional 5 min for a complete absorption of the
solution. After surgery, animals were monitored, and post-surgical care was provided. Behavioral
tests were performed at 6 months after injection and mice were euthanized for biochemical and
histological analysis. For biochemical studies, tissues were immediately dissected and frozen at 80° C. For histological studies, mice were perfused with PBS and 4 % PFA and brains were
removed, followed by fixation in 4% PFA overnight and transfer to 30% sucrose for cryoprotection.
Immunohistochemistry and quantitative analysis
Mice were perfused with PBS and 4 % PFA and brains were removed, followed by fixation in 4 %
PFA overnight and transfer to 30 % sucrose for cryoprotection. Immunohistochemistry (IHC) was
performed on 40 µm thick serial brain sections. For histological studies, free-floating sections were
blocked with 10 % goat serum in PBS with 0.2 % Triton X-100 and incubated with TH antibody
followed by incubation with biotin-conjugated anti-rabbit antibody. After three times of washing,
ABC reagent (Vector laboratories, Burlingame, CA) was added, and the sections were developed
using SigmaFast DAB peroxidase substrate (Sigma-Aldrich). Sections were counterstained with
Nissl (0.09 % thionin). For the quantification, both TH- and Nissl-positive DA neurons from the SNpc
region were counted by an investigator who was blind to genotypes or treatment condition with
randomly allocated groups through optical fractionators, the unbiased method for cell counting,
using a computer-assisted image analysis system consisting of an Axiophot photomicroscope (Carl
Zeiss) equipped with a computer controlled motorized stage (Ludl Electronics, Hawthorne, NY), a
Hitachi HV C20 camera, and Stereo Investigator software (MicroBright-Field, Williston, VT). The
total number of TH-stained neurons and Nissl counts were analyzed as previously described49.
Behavioral tests
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α-syn PFF injected WT or IL-6 KO mice and α-syn PFF mice treated with deferiprone in their
drinking water starting 1 week after injection (sham or PFF) and continuing until sacrifice were used
for evaluation of α-syn PFF-induced behavioral deficits assessed by the pole test and the grip
strength test. All the experiments were performed by investigators who are blind to genotypes or
treatment condition and randomly allocated to groups. Pole test. Mice were acclimatized in the
behavioral procedure room for 30 min. The pole was made of a 75 cm-long metal rod with 9 mm
diameter wrapped with bandage gauze. The mice were trained for two consecutive days with three
test trials per each training session. Mice were placed on the top of the pole (7.5 cm from the top
of the pole) facing head-up. The time to turn and total time taken to reach the base of the pole were
recorded. The maximum cutoff time to stop the test and recording was 60 sec. After each trial, the
pole was cleaned with 70 % ethanol. Grip strength test. Neuromuscular function was measured by
determining the maximal peak force developed by the mice using an apparatus (Bioseb, USA).
Mice were placed onto a metal grid to grasp with either fore or both limbs that are recorded as ‘fore
limb’ and ‘fore and hindlimb’, respectively. The tail was gently pulled and the force applied to the
grid before the mice lose grip was recorded as the peak tension displayed in grams (g).
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Figure 4-1. Lipopolysaccharide induces an interleukin-6 dependent cellular iron
sequestration response in cortical neurons. (A) LPS induced IL-6 dependent iron accumulation.
(B) LPS induced iron accumulation can be prevented by pre-treatment with oral iron chelator
deferiprone. (C) LPS induced partially IL-6 dependent Hmox1 mRNA upregulation in neurons. (D)
LPS induced partially iron-dependent Hmox1 mRNA upregulation in neurons. (E) LPS induced
partially IL-6 dependent increase in neuronal MDA. (F) LPS induced partially iron dependent
increase in neuronal MDA. (G) LPS induced IL-6 dependent changes in the neuronal iron
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transcriptome. All data are normalized to NSS-WT (not shown) and each box represents N of 5.
Data indicate mean, and where error bars are shown, ± SEM. */#P < 0.05, **/##P < 0.01, ***/###P <
0.001, ****/####P < 0.0001, by 2-way ANOVA (A-G) with Tukey’s HSD post hoc test. * denotes
comparison to NSS-WT group. # denotes comparison to LPS-WT group.
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Figure 4-2. Interleukin-6 is necessary for α-syn PFF mediated neuronal CISR and behavioral
deficits. (A) α-syn PFF induced IL-6 dependent neuronal iron accumulation. (B) α-syn PFF induced
IL-6 dependent Hmox1 mRNA upregulation in neurons. (C) α-syn PFF induced IL-6 dependent
increase in neuronal MDA. (D) α-syn PFF induced IL-6 dependent CISR mRNA elevation in
neurons. (E) α-syn PFF induced IL-6 dependent TH- and Nissl-positive neuronal loss. (F) α-syn
PFF induced IL-6 dependent decrease in neuronal TH and DAT protein levels. (G - H) α-syn PFF
induced IL-6 dependent deficit in pole test performance. (I - J) α-syn PFF induced IL-6 dependent
deficit in grip strength. Data indicate mean ± SEM. */#P < 0.05, **/##P < 0.01, ***/###P < 0.001,
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****/####P < 0.0001, by 2-way ANOVA (A-J) with Tukey’s HSD post hoc test. * denotes comparison
to NSS-WT group and # denotes comparison to LPS-WT group in panels A-D. In panels E-J,
comparison in shown directly.
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Figure 4-3. Iron chelation therapy reduces α-syn PFF mediated dopaminergic cell death and
behavioral deficits. (A) DFP treatment partially rescues α-syn PFF induced TH- and Nissl-positive
neuronal loss. (B) DFP treatment partially rescues α-syn PFF induced decrease in neuronal TH
and DAT protein levels. (C - D) DFP treatment reduces deficit in pole test performance of α-syn
PFF injected mice. (E - F) DFP treatment improves grip strength in α-syn PFF injected mice. Data
indicate mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, by 2-way ANOVA (A-F)
with Tukey’s HSD post hoc test.
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Figure 4-4. The molecular signature of CISR is present in Parkinson’s disease. (A - D) ZIP14,
TFRC, and HAMP mRNA levels are significantly increased in the SN of PD patients. (E - I) ZIP14,
TFRC, and DMT1 protein levels are increased in the SN of PD patients, whereas FPN protein levels
are decreased. Data indicate mean ± SEM. *P < 0.05, **P < 0.01 by unpaired student’s two-tailed
t-test.
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Figure S4-1. Isolation and enrichment of specific cell populations from murine cortical
tissue. (A) Schematic showing sequential isolation of individual cell populations using magnetic
microbeads. (B) ACSA2+ enriched cell populations express astrocyte-specific gene markers. (C)
ACSA2- CD11b+ enriched cell populations express microglia/macrophage-specific gene markers.
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gene markers. Data are expressed as relative fluorescent units.
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Figure S4-3. Interleukin-6 overexpression drives neuronal CISR gene expression. (A) IL-6
overexpressing mice exhibit cortical neuronal iron accumulation. (B) qPCR analysis of relative
mRNA levels of CISR genes in age- and sex-matched C57BL6/J wild-type (WT) and GFAP-IL6
transgenic mice. (C) In vitro cortical neurons accumulate ferrous iron in response to HIL-6. (D)
Hyper-IL-6 induces MDA accumulation in cultured cortical neurons in an iron-dependent manner.
(E) Hyper-IL-6 induces cultured neuron death in an iron-dependent manner. Data indicate mean ±
SEM. */#P < 0.05, **/##P < 0.01, ***/###P < 0.001, ****/####P < 0.0001, by unpaired student’s two-tailed
t-test (A-B) or one-way ANOVA with Holm-Sidak’s multiple comparisons test (C-E). In C, * denotes
a comparison to Fe2+. In D-E, * denotes a comparison to Fe2+ and # denotes a comparison to Fe2+
+ HIL-6.

61

A
ACSA2- CD11b+ Cells
NSS
KO

Zip14
Tf
Tfrc
Dmt1
Ftl
Fth
Hamp

LPS
WT

LPS
KO

*
*
*
*
*
*
*

#

*
*
*
*

#
#

*

5
4
3
2

#
#

#

1
0

Log2 Transformed

Rel. mRNA
(norm. to NSS inj. WT)

IP:
IL6:

-1

B
ACSA2+ Cells

Zip14
Tf
Tfrc
Dmt1
Ftl
Fth
Hamp

NSS
KO

LPS
WT

LPS
KO

*

#

*
*
*
*

*

3

#

2

*

1

5
4

#

0

Log2 Transformed

Rel. mRNA
(norm. to NSS inj. WT)

IP:
IL6:

-1

Figure S4-4. Lipopolysaccharide induces an interleukin-6 dependent increase in CISR gene
expression in non-neuronal cell populations. (A) LPS induced IL-6 dependent CISR
transcriptional profile in microglia/macrophage-enriched cell populations. All data are normalized
to NSS-WT (not shown) and each box represents N of 5. (B) LPS induced IL-6 dependent CISR
transcriptional profile in astrocyte-enriched cell populations. All data are normalized to NSS-WT
(not shown) and each box represents N of 5. Data indicate mean. */#P < 0.05 by 2-way ANOVA
with Tukey’s HSD post hoc test. * denotes comparison to NSS-WT group. # denotes comparison
to LPS-WT group.
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Figure S4-6. Other models of Parkinson’s disease demonstrate neuronal upregulation of
CISR genes. (A) Elevation of CISR gene mRNA levels in neurons from hA53T transgenic mice.
(B) Elevation of CISR gene mRNA levels in neurons from MPTP-injected mice. Data indicate mean
± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by unpaired student’s two-tailed t-test.
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Figure S4-7. Intrastriatal injection of α-syn preformed fibrils induces CISR gene expression
changes in glia. (A) α-syn PFF induced partially IL-6 dependent CISR mRNA elevation in
microglia/macrophage-enriched cell populations. (B) α-syn PFF induced partially IL-6 dependent
CISR mRNA elevation in astrocyte-enriched cell populations. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001, by 2-way ANOVA with Tukey’s HSD post hoc test. * denotes a comparison to PBSWT.
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Figure S4-8. CISR gene expression is detectable in bulk brain tissue. (A) Elevation of CISR
gene mRNA levels in bulk brain tissue from α-syn PFF-injected mice. (B) Elevation of CISR gene
mRNA levels in bulk brain tissue from hA53T transgenic mice. Data indicate mean ± SEM. *P <
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Table S4-1. Human post-mortem tissues used in Fig. 4-4
Group
Diagnosis
Age
Control

PD

Sex

Race

PMD

1. Control

74

M

W

4

2. Control

79

M

W

16

3. Control

89

M

W

8.5

4. Control

69

F

W

14

5. Control

71

M

W

16

1. PD w/Dementia, Neuro. Degen,
Occipital Infarct

83

M

W

5

2. PD w/Dementia

76

M

W

17

3. PD w/Dementia

73

M

W

6.5

4. PD, Multiple Infarcts/ContusionsSmall, Old

80

F

W

6

5. PD w/Dementia

65

M

W

21

Abbreviations: PD, Parkinson’s disease; W, white; PMD, post-mortem delay (days).
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Table S4-2. List of antibodies used in this study
Antibody
Source
TH

Novus Biologicals

Identifier

Dilution

NB300-19

1:2,000 (WB)
1:1,000 (IHC)

DAT

Sigma

D6944

1:1,000 (WB)

ZIP14

Thermo Fisher Scientific

PA5-21077

1:1,000 (WB)

DMT1

Proteintech

20507-1-AP

1:1,000 (WB)

TFR1

Invitrogen

13-6800

1:1,000 (WB)

FPN

Thermo Fisher Scientific

PA5-64232

1:1,000 (WB)

ACSA-2

Miltenyi Biotec

130-097-678

-

CD11b

Miltenyi Biotec

130-126-725

-

O4

Miltenyi Biotec

130-094-543

-

CD31

Miltenyi Biotec

130-097-418

-

β-actin-HRP

Sigma

A3854

1:20,000 (WB)

Abbreviations: TH, Tyrosine hydroxylase; DAT, Dopamine transporter; ZIP14, ; DMT1, Divalent
metal transporter 1; FPN, Ferroportin; ACSA-2, Astrocyte cell surface antigen-2; HRP, Horseradish
peroxidase; WB, western blot; IHC, immunohistochemistry.
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CHAPTER 5: INFLAMMATORY ADIPOSE ACTIVATES A NUTRITIONAL IMMUNITY
PATHWAY LEADING TO RETINAL DYSFUNCTION
Introduction
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the United
States among those older than 50 years of age (Rein et al., 2009). The prevalence of AMD is
expected to rise as the U.S. population ages, affecting more than 17 million Americans by 2050
(Rein et al., 2009). Therapies for AMD remain limited. Anti-VEGF biologics have shown a dramatic
ability to slow, but not halt, the progression of neovascular AMD, a subtype of AMD representing
only ~10% of all cases (Keenan et al., 2020). Unfortunately, there are no therapeutics available to
slow progression of non-neovascular AMD, which constitutes ~90% of cases.
The pathophysiology of AMD is characterized by toxic oxidative stress (Beatty et al., 2000; Datta
et al., 2017; AREDS 2 Group, 2013) and chronic inflammation (Nussenblatt et al., 2014) leading to
retinal pigment epithelium (RPE) injury (Hanus et al., 2015) and photoreceptor death. Previous
work has shown that iron, a potent cofactor in the formation of reactive oxygen species (McCord,
1974; McCord and Day, 1978), accumulates in AMD RPE (Hahn et al., 2003).
Since Hahn et al. (2003), multiple studies have linked AMD to iron. Sequence variants in iron
regulatory genes confer genetic risk for AMD (Wysokinski et al., 2011, 2012, 2014, 2015).
Exogenous iron supplementation, via intravenous injections of iron-sucrose, in wild-type mice and
a 43-year-old woman receiving therapy for anemia, were associated with AMD-like retinopathy
(Song et al., 2016). In vitro and in vivo work have established that elevated iron levels upregulate
RPE synthesis and secretion of complement component 3 (C3) (Li et al., 2015) and amyloid-β (Guo
et al., 2014), two constituents of sub-RPE deposits known as drusen, a key histopathological
feature of AMD. Together these data point to a potential role for iron in the pathogenesis of AMD.
Disruption of iron homeostasis in hereditary diseases is sufficient to cause retinal disease in both
humans and animal models. Iron overload diseases, including thalassemia (Bhoiwala and Dunaief,
2016) and Friedreich’s Ataxia (Leruez et al., 2014), can both cause RPE abnormalities. In
aceruloplasminemia, loss of ferroxidase ceruloplasmin triggers iron accumulation in the pancreas,
brain and retina, leading to diabetes, dementia and retinal degeneration (Dunaief et al., 2005). In
select cases, patients with aceruloplasminemia exhibit early onset AMD (Dunaief et al., 2005). The
analogous mouse model, lacking ceruloplasmin and its homolog, hephaestin (Cp/Heph DKO),
exhibits retinal iron accumulation with basal laminar deposits, RPE and photoreceptor degeneration
and subretinal neovascularization (Hahn et al., 2004). The ocular findings in Cp/Heph DKO animals
have been replicated in other animal models of iron accumulation, including Hepcidin KO mice
(Hadziahmetovic et al., 2011a) and Bmp6 KO mice (Hadziahmetovic et al., 2011b). Together these
data demonstrate that iron accumulation is sufficient for retinal degeneration with features of AMD.
Iron chelation therapy is protective against a diverse range of in vitro and in vivo retinal insults. In
vitro, iron chelation reduces RPE death triggered by peroxide, staurosporine and Fas ligand
(Lukinova et al., 2009). In vivo, iron chelation is protective against RPE degeneration caused by
the oxidant sodium iodate (Hadziahmetovic et al., 2012). Thus, iron exacerbates retinal
degeneration secondary to a wide range of insults. Despite the links between iron and AMD, the
sufficiency of iron for retinal degeneration, and the protective ability of iron chelators, the cause of
iron accumulation in AMD is unknown.
High fat intake, also known as a “Western diet,” is associated with increased risk of AMD (Chiu et
al., 2014; Mares-Perlman et al., 1995; Seddon et al., 2001, 2003a). In mice, high fat diet potentiates
the development of AMD-like features in the retina (Andriessen et al., 2016; Dasari et al., 2011;
Espinosa-Heidmann et al., 2006; Fujihara et al., 2009; Jun et al., 2018; Landowski et al., 2019;
Roddy et al., 2019; Toomey et al., 2015; Tuzcu et al., 2017; Zhang et al., 2018). As in AMD, mice
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fed a high fat diet exhibit increased markers of both systemic and local immune activation in the
central nervous system (Guilherme et al., 2008; Guo et al., 2020; Lumeng and Saltiel, 2011;
Vandanmagsar et al., 2011).
Given the independent associations between AMD and high fat diet (Chiu et al., 2014; MaresPerlman et al., 1995; Seddon et al., 2001, 2003a) and AMD and iron accumulation (Hahn et al.,
2003), we tested the hypothesis that high fat diet induces RPE iron accumulation and oxidative
stress. Herein we show that high fat diet leads to the formation of inflammatory adipose tissue
which releases interleukin-1β (IL-1β). IL-1β produced by visceral adipose, or locally in ocular
tissues, activates the cellular iron sequestration response (CISR), a maladaptive chronic
application of nutritional immunity, triggering the deleterious uptake of iron into RPE cells. This in
turn leads to RPE oxidative stress and electrophysiological dysfunction. Using human donor tissue,
we show that hallmarks of the CISR and IL-1β production pathway are observed in AMD ocular
tissue suggesting that the CISR, identified using the high fat diet model, may be active in AMD and
contribute to RPE iron accumulation, oxidative stress, and death.
Results
High fat diet induces iron-dependent RPE dysfunction
C57BL/6J wild-type (WT) mice were fed a diet of 10% calories from fat (low fat diet, LFD) or 60%
calories from fat (high fat diet, HFD) alone or in combination with the oral iron chelator, deferiprone
(DFP), for 12 weeks (from 3 months to 6 months of age). Deferiprone has been shown previously
to diminish RPE iron levels (Hadziahmetovic et al., 2011c). HFD mice gained weight relative to LFD
mice, regardless of deferiprone treatment (Fig. 5-1A). The mass of visceral (VAT) and
subcutaneous (SAT) fat pads was not affected by deferiprone (Fig. 5-1B). Deferiprone and/or HFD
had no effect on glycemic control (Fig. 5-1C) after 12 weeks of treatment, eliminating hyperglycemia
as a potential confounding variable in our analyses. We performed inductively coupled plasma
mass spectrometry to quantify intracellular iron in retinal pigment epithelium (RPE) isolated from
mice in all four groups. HFD mice exhibited increased intracellular RPE iron relative to both LFD
groups and HFD mice treated with deferiprone (Fig. 5-1D). Iron can act as a potent generator of
reactive oxygen species (ROS) which can induce oxidative stress, a pathological feature of AMD
(Beatty et al., 2000; Brantley et al., 2012; Jun et al., 2018; McCord, 1974; McCord and Day, 1978).
To investigate oxidative stress in the RPE, we measured levels of malondialdehyde (MDA), an
oxidized lipid product, and Hmox1 mRNA, which is upregulated by oxidative stress. Levels of both
MDA and Hmox1 mRNA increased in the HFD RPE and were reduced by treatment with
deferiprone (Fig. 5-1E-F). To assess RPE function, we performed RPE electrophysiology in vivo
using electroretinography. In response to light pulses the RPE exhibits a slow electrical polarization
(c-wave) whose amplitude can be quantified as a marker of RPE cell health (Wu et al., 2004). The
RPE in HFD mice exhibited a c-wave amplitude deficit that was rescued by iron chelation (Fig. 51G). Together these data demonstrate that HFD induces RPE iron accumulation, oxidative stress
and electrical dysfunction which can be partially rescued by iron chelation therapy.
IL-1β is necessary for HFD-induced RPE iron accumulation and dysfunction
Although iron accumulation contributes to HFD-induced RPE dysfunction, the cause of iron
accumulation in the HFD mouse is not known. Previous work has shown that pro-inflammatory
cytokine interleukin 1β (IL-1β) can affect iron homeostasis (Kanamori et al., 2017; Shanmugam et
al., 2015; Silva et al., 2019) and is produced by inflamed adipose tissue (Vandanmagsar et al.,
2011). Additionally, IL-1β’s receptor, IL1R1, is expressed human primary RPE (Shi et al., 2008)
and mouse RPE (data not shown). We hypothesized that IL-1β triggers RPE iron accumulation. To
test this hypothesis, we treated cultured fetal human RPE cells (fRPE) with media or recombinant
IL-1β (rIL-1β) in the presence of transferrin-bound radioactive ferric iron (Tf•55Fe3+) or labile
radioactive ferrous iron (55Fe2+), the two physiologic forms of extracellular iron. rIL-1β induced
ferrous, but not ferric iron accumulation (Fig. 5-2A). This was accompanied by increased
expression of three iron importers, TfRC, DMT1, and ZIP14 (Fig. 5-2B). Although TfRC participates
in transferrin-bound ferric iron import (Daher and Karim, 2017), both DMT1 (Lane et al., 2010) and
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ZIP14 (Liuzzi et al., 2006) have been linked to ferrous iron uptake. Given IL-1β’s ability to trigger
RPE iron accumulation in vitro, and a pre-existing literature on IL-1β upregulation in inflammatory
fat (Vandanmagsar et al., 2011), we hypothesized that IL-1β is necessary for RPE iron
accumulation in the HFD mouse. To test this, we fed WT and Il1b-/- (KO) mice either a low fat or
high fat diet for 12 weeks as described above. Genotype had no effect on total mass gained across
the treatment period (Fig. 5-2C) or on the distribution of fat across different fat pads (Fig. 5-2D).
Genotype and/or diet also had no effect on glycemic control (Fig. 5-2E). HFD-fed mice exhibited
IL-1β-dependent upregulation of Tfrc, Dmt1, and Zip14 in RPE, consistent with the gene expression
changes observed in rIL-1β-treated fRPE cells. In addition to upregulation of these three iron
importers, RPE from HFD mice also exhibited an IL-1β-dependent upregulation of Hamp, which
encodes the peptide hormone hepcidin. Hepcidin negatively regulates iron export from the only
known mammalian iron exporter, ferroportin (Fpn) (Fig. 5-2F). RPE was not the only source of
retinal hepcidin production. CD11b+ cells isolated from retina also upregulated Hamp in the HFDfed mice in an IL-1β-dependent manner (Fig. 5-2G). HFD-induced RPE iron accumulation (Fig. 52H), MDA elevation (Fig. 5-2I) and Hmox1 upregulation (Fig. 5-2J) were all IL-1β-dependent, as
were the c-wave deficits observed in mice fed a high fat diet (Fig. 5-2K). Together these data
suggest that obesity-associated IL-1β, via upregulation of iron importers and hepcidin, induces RPE
iron sequestration, oxidative stress, and dysfunction.
Activation of systemic and local inflammatory circuits contribute to IL-1β production
Given the critical role of IL-1β in RPE iron accumulation we wanted to identify sources of obesityassociated IL-1β which could contribute to RPE iron accumulation. The RPE itself is sandwiched
between the neurosensory retina, located inside the blood-retina barrier, and the choriocapillaris,
a highly vascular tissue that bathes the basolateral aspect of the RPE in plasma via fenestrated
capillaries (Fig. 5-3A). Previous studies of non-diabetic, high fat diet-fed mice have shown elevated
levels of IL-1β protein in visceral adipose tissue and serum (Guo et al., 2020). We measured IL-1β
protein levels by ELISA in a well-characterized subtype of visceral adipose tissue, epididymal white
adipose tissue (eWAT), retina, choroid, and serum. IL-1β protein levels were elevated in each
tissue in HFD mice (Fig. 5-3B), suggesting that multiple sources of IL-1β could contribute to RPE
CISR.
Previous data has shown that both mature adipocytes and adipose tissue resident macrophages
produce IL-1β following high fat diet and formation of inflammatory adipose tissue (Chawla et al.,
2011). Given local elevations in IL-1β in the choroid and retina, we wanted to identify candidate cell
types that could be responsible for local IL-1β production. IL-1β is a pro-inflammatory cytokine
produced as a 35kDa precursor (pro-IL-1β). Following NLRP3 inflammasome activation, it is
cleaved by the protease caspase-1 into a 17kDa active form (IL-1β). Mature IL-1β is secreted and
can bind IL-1R1 (Weber et al., 2010). Based on previous data implicating retinal CD11b+ cells in
the production of retinal IL-1β (Natoli et al., 2017), we hypothesized that CD11b+ cells in the retina
and choroid contribute to IL-1β production in the HFD model. Unfortunately, in vivo measurements
of cell-type specific IL-1β secretion are extremely challenging. To determine if CD11b+ cells in the
HFD model are capable of IL-1β production, we defined a state of IL-1β production competence
based on expression of Il1b, Nlrp3 and Casp1. CD11b+ cells from retina (Fig. 5-3C) and choroid
(Fig. 5-3D) exhibited co-expression of Il1b, Nlrp3, and Casp1. In CD11b+ cells from both sources,
Il1b mRNA levels were upregulated in the HFD mice (Fig. 5-3C, D).
To dissect the contribution of adipose tissue-derived IL-1β to obesity-associated RPE iron
accumulation, Il1b-/- mice on a high fat diet for 1.5 months were given an eWAT transplant from
Il1b-/- or Il1b+/+ donor mice. Following transplant, mice were maintained on a high fat diet for
another 1.5 months before they were euthanized (Fig. 5-3E). IL-1β protein levels were measured
in serum, choroid, and neurosensory retina using IL-1β ELISA, and compared to Il1b+/+ mice
maintained on LFD or HFD for 3 months with a sham transplant surgery at 1.5 months. IL-1β protein
levels in the serum were elevated in Il1b-/- HFD mice that received transplant tissue from HFD WT
but not HFD Il1b-/- mice, suggesting that serum IL-1β is at least partially derived from adipose
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tissue (Fig. 5-3F). Likewise, choroidal IL-1β protein levels were elevated in Il1b-/- mice that received
transplant tissue from WT but not Il1b-/- mice (Fig. 5-3G). Retina IL-1β levels were low, but not
undetectable following WT adipose transplant (Fig. 5-3H). This may represent contamination from
the serum/choroid, or transport of IL-1β into the retina across the blood-retina barrier. Finally, we
measured RPE iron accumulation in each of the four groups and found that WT eWAT transplant
into Il1b-/- mice was sufficient to trigger RPE iron accumulation (Fig. 5-3I). Together the data in Fig
5-3F-I suggest that systemic IL-1β produced by eWAT is sufficient to trigger RPE iron accumulation.
Data from WT LFD and HFD-fed mice show that IL-1β levels are elevated in multiple compartments
including the neurosensory retina (Fig. 5-3B). However, restoration of systemic levels of IL-1β in
the serum and choroid, using eWAT transplant, was not sufficient to increase retinal IL-1β levels,
suggesting that the elevated IL-1β in retina caused by HFD in WT mice (Fig 5-3B) results from local
production of IL-1β within the retina. To determine if retinal IL-1β is sufficient to induce RPE CISR,
adult WT mice were given an intravitreal injection of PBS or rIL-1β (Fig. 5-3J). iCP-MS performed
on RPE isolated 8 hours after injection demonstrated an increase in RPE iron in the rIL-1β injected
eyes compared to the PBS injected eyes (Fig. 5-3K). These data demonstrate that IL-1β in the
retina is also sufficient to induce RPE CISR.
Together, the data in Fig. 5-3B-K suggest that systemic and local sources of IL-1β, including
inflammatory adipose tissue, choroidal macrophages and retinal microglia, contribute to RPE CISR
in this obese, non-diabetic mouse model.
Hallmarks of IL-1β-dependent CISR are observed in AMD patients
Previous work has linked inflammasome activation and IL-1β signaling to the AMD retina (Celkova
et al., 2015; Zhao et al., 2015). The RPE of patients with either form of advanced AMD (geographic
atrophy and choroidal neovascularization) exhibit elevated levels of NLRP3 inflammasome
components, NLRP3 inflammasome activation markers (caspase-1) and IL-1β mRNA (Celkova et
al., 2015; Oh et al., 1999; Tseng et al., 2013; Zhao et al., 2015). Pro-IL-1β and mature IL-1β levels
are increased in the vitreous of patients with neovascular AMD (Zhao et al., 2015). Mature IL-1β
protein levels are elevated in the serum of obese patients (Chawla et al., 2011; Wu and Ballantyne,
2020) and patients with AMD (Nassar et al., 2015). Furthermore, iron itself can activate the RPE
inflammasome, which may lead to a vicious cycle (Gelfand et al., 2015).
Genetic risk factors associated with AMD, including single nucleotide polymorphisms in both
complement factor H and matrix metalloproteinases, are associated with elevated serum levels of
IL-1β (Budiene et al., 2018; Cao et al., 2013). In patients with geographic atrophy, sites of cone
outer segment atrophy are associated with macrophages in retinal tissue sections. In vivo,
macrophages in the retina express elevated levels of IL-1β, suggesting that IL-1β may play a role
in cone outer segment atrophy and disease progression (Doyle et al., 2014). IL-1β treatment of
RPE leads to cell swelling and atrophy in vivo (Doyle et al., 2014). Components of drusen, including
Aβ (1-40), increase the expression of IL-1β and inflammasome components in vivo (Celkova et al.,
2015). Together these data suggest that IL-1β may contribute to AMD pathogenesis.
Based on our findings, IL-1β in the systemic circulation, choroid, or neurosensory retina may
contribute to RPE iron accumulation (Fig. 5-3). Previous work has shown that IL-1β protein levels
are elevated in serum from AMD patients (Nassar et al., 2015), suggesting that systemic IL-1β
production may trigger RPE CISR in AMD. Our data also implicate CD11b+ cells in the choroid and
retina in local IL-1β production. To determine which cell populations are competent to produce IL1β in humans, we used single-cell RNA sequencing (sc-RNAseq) to identify cells expressing IL1B,
NLRP3 and CASP1. Choroidal sc-RNAseq data from human donors (4 with no ocular disease, 2
with AMD) showed that 58.6% of choroidal macrophages were Il1b+ Nlrp3+ Casp1+ mRNA triplepositive (Fig. 5-4A). This expression pattern was specific to macrophages (Fig. 5-4B). Comparing
the expression of these three RNAs in AMD vs control choroidal macrophages demonstrated
significant IL1B mRNA enrichment in macrophages isolated from AMD cases (Fig. 5-4C).
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sc-RNAseq performed on neurosensory retina from healthy human donors demonstrated
significant enrichment for IL1B, NLRP3 and CASP1 transcripts in microglia compared to other
retinal cell types (Fig. 5-4D-G), consistent with our observation that CD11b+ cells in the HFD mouse
retina upregulated Il1b (Fig. 5-3C). Using the same dataset, we also show that HAMP, a negative
regulator of iron export, is expressed specifically in retinal microglia (Fig. 5-4H). This is in line with
our data showing that retinal CD11b+ cells (enriched for microglia) upregulate Hamp in HFD-fed
mice (Fig. 5-2G) and recent work which showed that HAMP transcripts are enriched in AMD
microglia from early AMD Minnesota Grading System (Minnesota Grading System 2, MGS2)
retinas compared to normal MGS1 retinas (Lyu et al., 2019). Together these data support the
hypothesis that microglia-produced hepcidin (gene name Hamp or HAMP) may contribute to RPE
CISR.
Bulk neurosensory retina RNAseq from control, early AMD and late AMD donors demonstrated
enrichment for IL1B, NLRP3, and CASP1 transcripts correlated with disease progression in
samples from macular retina (MR) and enrichment for IL1B in late AMD peripheral retina (Fig. 54I).
While sc-RNAseq may be sufficient to determine which cell types are competent to produce IL-1β,
ultimately mature IL-1β must be produced to elicit the RPE CISR. We compared IL-1β protein levels
in NSR samples from MGS-1 (no AMD) vs MGS2 (early AMD) and MGS3 (intermediate AMD) eyes
(see Supplementary Table 5-1 for donor information). IL-1β protein levels were significantly
elevated in MGS2/3 retinas compared to MGS1 retinas (Fig. 5-4J).
Discussion
We show that high fat diet-induced IL-1β triggers RPE iron accumulation, oxidative stress and
electrophysiological dysfunction in obese, non-diabetic mice. We term this IL-1β-dependent RPE
iron accumulation the cellular iron sequestration response (CISR). Systemic/choroidal or retinal IL1β were sufficient to induce CISR. Using the HFD mouse model and RNAseq data from human
donors we implicate choroidal macrophages and retinal microglia in the IL-1β production necessary
for RPE CISR. Together these data demonstrate a pathway of inflammation-driven iron
accumulation in a mouse model with links to age-related macular degeneration (AMD).
Inflammation is a key regulator of iron homeostasis beyond the CISR mechanism proposed herein.
Transition metals, including iron, are essential for prokaryotic and eukaryotic life. To defend against
pathogens, vertebrate immune systems can sequester iron as a bacteriostatic mechanism of host
defense termed “nutritional immunity” (Lopez and Skaar, 2018; Soares and Weiss, 2015). Anemia
of inflammation (AI), a common clinical condition associated with acute (critical illness, infection)
and chronic (cancer/hematological malignancies, immune-mediated disease, inflammatory
disease, obesity) inflammation, is a maladaptive sequela of nutritional immunity. In AI, activation of
the innate immune system drives decreased iron absorption from the gut and iron sequestration in
macrophages via upregulation of cellular iron import and downregulation of iron export (Soares and
Hamza, 2016; Weiss et al., 2019). These mechanisms, in combination with other pathways,
decrease serum iron concentration, starving the bone marrow of the iron necessary for hemoglobin
synthesis (Weiss et al., 2019). The activation of iron sequestration in macrophages described in AI
is reminiscent of the same pathways we have described in the retina and involve the same
regulators (IL-1β) and effectors (hepcidin). Of note, AI is activated by several pro-inflammatory
cytokines, primarily IL-1β and IL-6 (Weiss et al., 2019). We pursued IL-1β in our studies after
determining that IL-6 treatment was not sufficient to induce CISR iron accumulation or
transcriptional changes in fRPE (data not shown) or in vivo in mouse RPE (data not shown).
AMD is associated with elevated serum measures of inflammation, including C-reactive protein,
TNF-α, IL-6, and IL-1β (Haas et al., 2015; Klein et al., 2014; Nassar et al., 2015). Systemic levels
of IL-6 correlate with progression of geographic atrophy (Nielsen et al., 2019). Genetic risk factors
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associated with AMD, including single nucleotide polymorphisms in both complement factor H and
matrix metalloproteinases, are associated with higher serum levels of IL-1β (Budiene et al., 2018;
Cao et al., 2013). These associations support the link between AMD and systemic inflammation. In
humans and mice, visceral adiposity and obesity are associated with systemic inflammation,
including elevated levels of serum IL-1β (Chawla et al., 2011; Wu and Ballantyne, 2020). These
data, in combination with our own, suggest that systemic inflammation, driven by visceral adiposity,
may influence the development and progression of AMD.
Previous work has demonstrated an association between dietary fat, visceral adiposity and
progression of AMD (Adams et al., 2011; Haas et al., 2015; Seddon et al., 2001, 2003b). The link
between high fat diet and AMD has also been borne out in mouse models representing features of
AMD. High fat diet in combination with smoke exposure or ingestion of smoke-related redox
molecule, HQ, produced a mouse with sub-RPE deposits, thickening of Bruch’s membrane (BM),
and deposits within BM – all features of AMD (Espinosa-Heidmann et al., 2006). Sub-RPE
deposits, complement activation, RPE damage and visual function impairment are observed in
aged mice carrying genetic risk associated with AMD and fed a high fat diet (Toomey et al., 2015).
Basal laminar deposits and BM thickening with RPE and photoreceptor degeneration are observed
in PGC-1α KO mice fed a high fat diet (Zhang et al., 2018). In each of these models, high fat diet,
in combination with other factors associated with AMD, induces AMD-like phenotypes in mice. In
our obese, non-diabetic mice, we did not observe photoreceptor/RPE cell death or changes in RPE
morphology. Based on these findings, and the findings of other groups using high fat diet, high
cholesterol diet, age, smoke exposure or genetic mutations alone, or in combination to model AMD,
it seems likely that individual risk factors alone are not sufficient for AMD (Espinosa-Heidmann et
al., 2006; Toomey et al., 2015; Zhang et al., 2018). This reinforces a multi-hit hypothesis of AMD
pathogenesis (Fritsche et al., 2014).
While we link IL-1β to RPE iron accumulation, IL-1β is known to regulate other pathways including
adaptive and maladaptive CNS angiogenesis. Following stroke, IL-1β upregulates pro-angiogenic
factor PTX3 (Rodriguez-Grande et al., 2015) IL-1β is also able to induce VEGF expression and
secretion, likely through stabilization of HIF-1α (Alagappan et al., 2005; Jung et al., 2003; Ryan et
al., 1998). VEGF is known to regulate neovascularization in the retina and contributes to
neovascular AMD (Solomon et al., 2019). It is therefore possible that obesity driven IL-1β
upregulation may also contribute to retinal neovascularization.
Herein, we implicate CD11b+ cells of the retina and choroid in the production of IL-1β that triggers
RPE CISR, based on expression of Il1b, Nlrp3, and Casp1 mRNA. We define triple positive cells
as “competent for IL-1β production.” However, release of IL-1β is itself a regulated step in the
inflammatory cascade that can occur in gasdermin-dependent and -independent pathways
(Monteleone et al., 2018). Our data showing that eWAT transplantation from HFD/WT into
HFD/Il1b-/- mice can induce RPE CISR also suggests that systemic IL-1β can induce RPE CISR.
Future work is necessary to understand the molecular signals that lead to microglial and choroidal
macrophage IL-1β production and secretion in the high fat diet model and AMD.
Of note, CD11b+ cells may not be the only sources of IL-1β in the AMD retina. Previous work has
documented increased NLRP3 inflammasome components and IL1B mRNA in the RPE of patients
with either form of advanced AMD (geographic atrophy or choroidal neovascularization (Celkova
et al., 2015; Oh et al., 1999; Tseng et al., 2013; Zhao et al., 2015). Although the RPE of the HFD
mice did not upregulate Il1b, Nlrp3 or Casp1 (data not shown), AMD RPE may serve as a source
of IL-1β. This IL-1β could act in an autocrine fashion, triggering RPE CISR. Since iron itself is
capable of activating the RPE inflammasome (Gelfand et al., 2015), autocrine RPE IL-1β signaling
could trigger a vicious cycle of iron and inflammation leading to RPE degeneration.
The data herein spur a number of avenues for future exploration. Future work should determine
whether the CISR is reversible and whether change in diet can reduce RPE iron accumulation,
78

oxidative stress and dysfunction. Additionally, we chose to focus our work on the RPE, however
CISR may occur in other cells types, including the photoreceptors, which have previously been
shown to exhibit iron accumulation in AMD (Dentchev et al., 2005). CISR in microglia may also
lead to further inflammation based on previous work showing that iron accumulation leads to
microglial production of cytokines (Nnah et al., 2019). Finally, prospective studies should assess
the role of systemic inflammation in obesity as a determinant of AMD risk. Beyond the context of
AMD, other CNS diseases exhibit co-incident iron accumulation, neuroinflammation and
degeneration, including Parkinson’s disease (Jiang et al., 2016; Wood, 2020) and Alzheimer’s
disease (Connor et al., 1992). It is therefore possible that the CISR mechanism described herein
may be relevant to those neurodegenerative diseases as well as chronic systemic inflammatory
diseases.
Iron accumulation in AMD RPE was first described in 2003. Since then, multiple publications have
demonstrated that iron accumulation is sufficient for retinal degeneration with features of AMD,
including RPE oxidative stress, dysfunction and retinal degeneration with neovascularization.
Furthermore, deferiprone, an iron chelator, reduces RPE iron accumulation and prevents retinal
degeneration in these same animal models. However, the potential use of deferiprone in AMD has
been hampered by its side effects, including rare, but potentially deadly, neutropenia and
agranulocytosis which require weekly monitoring. Weekly monitoring may not be feasible for
patients with AMD who may require decades of chelation therapy to provide continued protection
from RPE stress. Our findings provide an AMD-linked mechanism of action for RPE iron
accumulation, oxidative stress, and RPE dysfunction which we term the cellular iron sequestration
response or CISR. Activation of the CISR, via IL-1β, may contribute to RPE iron accumulation in
AMD. By identifying IL-1β as a potential causative factor, we open additional translational avenues
to reduce iron accumulation in the AMD retina, including intravitreal or systemic administration of
FDA-approved anti-IL-1β therapies.
Materials & Methods
Animals
For all experiments, mice were housed in a ventilated rack with ad libitum access to food and water
under a 12hr light/dark schedule (lights-on at 6:00AM). 12 week old (wo) male C57BL6/J WT
(Jackson Laboratory, 000664) and IL-1β KO mice (Horai et al., 1998), generously provided by Dr.
Iwakura, University of Tokyo, were bred in-house for these experiments. Mice were fed either a low
fat diet (Research Diets, D12450) or high fat diet (Research Diets, D12492) starting at 12 wo until
24 wo. Where indicated, mice were treated with 0.5 mg/mL deferiprone (ApoPharma, Toronto,
Canada) dissolved in their drinking water starting at 12 wo and continuing until euthanasia.
Previous data have shown that this dose is sufficient to reduce iron-induced neurodegeneration in
mice (Hadziahmetovic et al., 2011c, 2012; Song et al., 2012). All housing, breeding, and
procedures were performed according to the NIH Guide for the Care and Use of Experimental
Animals, ARVO standards for the use of animals and approved by the University of Pennsylvania
Animal Care and Use Committee.
Inductively Coupled Plasma Mass Spectrometry
Samples were analyzed for metals using a Nexion 300D (Perkin Elmer, Shelton, CT). The analytical
standards were purchased from SCP (Champlain, NY) and trace metal grade nitric acid was
purchased from Fisher Scientific (Pittsburgh, PA). All dilutions will be done using in-house
deionized water (≥18 MΩ) obtained from a water purification system (EMD Millipore, Billerica, MA).
The dried bovine liver sample (1577 C) used as reference material was obtained from NIST
(National Institute of Standards and Technology, Gaithersburg, MD). The tissue samples were dried
overnight in an oven set at 70°C and then weighed into Teflon PFA vials (Savillex, Minnetonka,
MN). The dried tissue samples were then digested overnight with 20 times the quantity
(weight/volume) of 70% nitric acid at 70°C. A 0.1 mL portion of the digested tissue sample was
then mixed with 0.05 mL of 2 ppm internal standard containing Ge (germanium), In (indium), Tb
(terbium), and Y (yttrium) and the mixture was diluted with deionized water to a final volume of 5
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mL for analysis. The concentration of each metal in the submitted sample was measured using a
calibration curve of aqueous standards prepared at four different concentrations of each metal. The
accuracy of the results was monitored by analyzing reference material (NIST 1577C) with known
values of metals of interest with each batch of samples. Total iron measurements for each sample
were normalized to the number of cells in the sample.
MDA ELISA
MDA competitive ELISA kit from Abcam (ab238537) was used accounting to manufacturer’s
protocol. Briefly, isolated RPE cells were lysed and cell lysates were placed in an MDA conjugate
coated plate. After incubation the wells of the plate were labeled with an HRP-conjugate secondary
antibody. Absorbance at 450nm was quantified and compared to a standard curve to quantify the
amount of MDA present in the experimental samples. All measurements shown herein are the
average of two technical replicates.
Quantitative PCR
RNA isolation was performed according to the manufacturer’s protocol (RNeasy kit; Qiagen). cDNA
was synthesized with reverse transcription agents (TaqMan Reverse Transcription Reagents,
Applied Biosystems) according to the manufacturer’s protocol. Gene expression was analyzed
using a commercial sequence detection system (ABI Prism 7500, Applied Biosystems). All
reactions were performed in technical triplicate. Probes were obtained from ThermoFisher
Scientific.
Electroretinography
Mice were dark-adapted overnight, anesthetized with a ketamine-xylazine cocktail delivered
intramuscularly, their pupils were dilated with 1% tropicamide (Alcon Laboratories, Fort Worth,
TX), and the animals were placed on a stage maintained at 370C. Custom made clear plastic
contact lenses with embedded platinum wires served as recording electrodes, and a platinum wire
loop inserted into the animal’s mouth served as the reference electrode. Electroretinograms were
elicited and recorded with an Espion E3 apparatus (Diagnosys LLC, Lowell, MA). C-wave
responses were obtained with stimuli of 0.1, 1, 10 and 100 scot cd s m-2 delivered at 10 s intervals.
Values and representative recordings reported herein were recorded at 100 scot cd s m-2.
Fetal RPE Cell Culture & Gene Expression Studies
Highly-polarized primary RPE monolayers were established using donor fetal eyes as previously
described (Lyssenko et al., 2018). Each eye was placed in an antibiotic-antimycotic solution and
rinsed with Hank’s buffered salt solution. The eyes were pinned onto a dissection stage, and the
cornea, vitreous, and lens were removed. The open eyes were transferred into a well of a 6 well
plate containing room temperature dispase solution in RPE medium/5% FBS and incubated for 45
min at 37°C in 5% CO2. The RPE medium was prepared as previously described (Lyssenko et al.,
2018). The retina was removed, and the RPE was peeled off the choroid-scleral tissue. The RPE
layer was collected into a 15 ml conical tube, gently shaken, and trypsinized to release RPE cells.
The cells were centrifuged, washed, transferred to a T-25 flask, and cultured in RPE medium/15%
FBS for 1 week and then in RPE medium/5% FBS for 1 month. By this time, the RPE cells were
highly pigmented and confluent at about 500,000 cells/cm2. The cells were transferred onto 0.4 μm
pore size polycarbonate 12-well plate inserts (Corning, NY, USA) that were coated with human
extracellular matrix, cultured for 5 weeks in RPE medium/15% FBS and then maintained in RPE
medium/2% FBS. The barrier function of the RPE monolayer was assessed by measuring
transepithelial electrical resistance (TEER), and all had above 450 mΩ. For IL-1β treatment cells
were placed in serum free media for 24 hours prior to start of experiment. After 24 hours, the fRPE
cells were treated with vehicle or 10 ng/ml IL-1β (Abcam, Ab9617) for 24 hours before harvest.
Fetal RPE Cell Culture Radiolabeled 55Fe Tracing Studies
To directly measure intracellular iron accumulation in response to IL-1β treatment, radiolabeled
55
Fe tracking studies were completed in IL-1β-treated fRPE cells. fRPE cells were grown on 12 well
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transwell plates (Corning, Corning, NY, USA). 24 hours before the start of the experiment, the cells
were placed into serum-free media. After 24 hours, the cells were given either vehicle or 10 ng/ml
IL-1β. After 24 hours of IL-1β treatment, iron uptake was assessed with 2 µM 55Fe in two forms,
i.e. as holo-Tf (Sigma-Aldrich, St. Louis, MO, USA) (Tf-55Fe3+) or as 55Fe2+ ascorbate. The
radiolabeled holo-transferrin was prepared by adding 100 µM 55Fe2+Cl3 to 100 µM apo-transferrin
made up in loading buffer consisting of 1 M Hepes KOH pH 7.5, 150 mM NaCl, 10 mM freshly
prepared sodium bicarbonate, incubating for 30 min on ice and rapidly centrifuging through a G25
column. This stock was diluted 1:50 into serum free medium to give a concentration of 2 µM iron
for the assay. The 55Fe2+ ascorbate was prepared by adding 1 mM sodium ascorbate (SigmaAldrich, St. Louis, MO, USA) to 100 μM 55Fe2+Cl3 in a small volume, incubating 10 min in air, and
then diluting 1:50 into serum free medium to give a concentration of 2 µM iron for the assay. Iron
uptake was allowed to proceed for 6 hours. After 6 hours, cell lysates were collected in 1X RIPA
buffer (Cell Signaling Technology, Danvers, MA, USA). 100ul of the cell lysate was added to a
scintillation tube with 1ml of scintillation liquid (Catalog #: SX20-5, Fisher Scientific, Pittsburgh, PA,
USA). The iron counts per minute (CPM) in the lysates were then measured in a scintillation
counter.
Magnetic Activated Cell Sorting for CD11b+ Cells
All cell sorting steps relied on Miltenyi Biotec Microbead Kits: Anti-ACSA-2 Microbead (Cat # 130097-678), Anti-CD11b Microbead (Cat # 130-126-725). Briefly, at each selection step Fc receptors
were blocked with an FcR Blocking Reagent. Cells were then incubated with a magnetically labeled
antibody targeting the epitope of interest (ACSA-2, CD11b). The cell suspension was passed
through an MS column (Miltenyi Biotec, Cat # 130-042-201) in a magnetic field so that magnetically
labeled cells remained in the column while unlabeled cells passed through the column. This
process was repeated twice over two separate MS columns to maximize purity of the isolated
population. Retinal CD11b+ cells were isolated by a two-step process: first selecting against
ACSA2 and then selecting for CD11b as described previously (Sterling et al., 2020). Choroidal
CD11b+ cells were isolated using a single positive selection step for CD11b.
IL-1β ELISA
Human and mouse IL-1β was measured in protein lysates and serum using kits from R&D Systems
(MLB00C or DLB50 R&D Systems) following the manufacturer’s instructions. All mice were
perfused prior to tissue harvest for all ELISA measurements on adipose tissue, retina, and choroid.
Epididymal White Adipose Tissue Transplant
Donors (both Il1b+/+ or Il1b-/- mice) and recipients (Il1b-/- mice) were maintained on a high fat diet
for 6 weeks. At 6 weeks epididymal white adipose tissue (EWAT) was harvested from donor mice
(Il1b+/+ or Il1b-/-) and transplanted into recipient mice. Briefly, an aseptic surgical area was
prepared, and mice were anesthetized using isoflurane. Following anesthesia, an abdominal skin
and peritoneal incision was made to expose the viscera. Donor EWAT was exposed and a scalpel
was used to expose the EWAT vasculature in the recipient. Donor EWAT tissue was sutured into
the host EWAT, proximal to the exposed vasculature. The peritoneal cavity and skin were closed,
and the mouse was fully alert before being returned to the animal colony. Mice were provided with
post-surgical antibiotics and analgesia. Recipient mice were maintained on a high fat diet for
another 6 weeks before euthanasia. Transplant tissue was assessed following euthanasia by gross
examination to determine if the donor tissue (marked by a non-absorbable suture) was well
vascularized. Mice in which the suture could not be located or where the tissue surrounding the
suture appeared poorly vascularized or necrotic were excluded from the study.
Intravitreal Injection
2 μg/ml recombinant murine IL-1β (Pharmingen, San Diego, CA, USA), diluted in 1XPBS, was
injected into the vitreous of the right eyes of C57BL/6J male mice, resulting in 2 ng of IL-1β protein
total delivered to the vitreous. The left eyes received intravitreal injections of vehicle, using a 10- µl
syringe (Hamilton, Martinsried, Germany) fitted with a 35-gauge needle. 2ng of IL-1β was chosen
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because in the 4.4μL volume of the mouse vitreous, the concentration of IL-1β was the same order
of magnitude as the concentration of IL-1β observed in neovascular AMD and polypoidal choroidal
vasculopathy (Zhao et al., 2015). After 8 hours the mice were euthanized, and eyes were processed
for analysis.
Choroid Single-Cell RNAseq
Previously published human choroidal single-cell RNA sequencing data was reprocessed from four
adult control donors and two adult AMD donors (GSE135922 donors 4-7, GSE149100 donors 2223) (Voigt et al., 2019, 2020a) using the Seurat R package (Butler et al., 2018). Using this data, we
investigated which cell type(s) expressed IL1B, NLRP3, and CASP1. All cells that expressed at
least one read of IL1B, NLRP3, and CASP1 were classified as ‘triple-positive’ cells for
visualizations. Differential expression analysis was performed between the macrophage cells from
AMD versus control donors using the FindMarkers function (using the Wilcoxon Rank Sum
test) within Seurat. Visualizations of single-cell RNA sequencing data were created with Spectacle
(Voigt et al., 2020b), which also allows for online interactive analysis of this dataset.
Neurosensory Retina Single-Cell RNAseq
The scRNA-seq data were generated from macular and peripheral retina taken from two healthy
adult donors using the 10X Genomics Chromium™ system (Lyu et al., 2019). Neither donor had a
known history of retinal disease, head or ocular trauma, significant refractive error, neurological
disease, diabetes, or uncontrolled hypertension. Cell types in the retina that expressed IL1B,
NLRP3, or CASP1 in at least 10% of their cells were classified as positively expressing the gene.
Expression output was mapped to the tSNE coordinates in R to produce the landscape plots.
Neurosensory Retina Bulk-RNAseq
The bulk RNA-data were generated from 13 macula samples (6 normal, 4 early AMD, and 3 late
AMD) and 15 periphery samples (8 normal, 4 early AMD, and 3 late AMD) taken from the retina of
15 adult donors (Lyu et al., 2019). RNA for the eye tissues was extracted using the AllPrep
DNA/RNA Mini Kit (Qiagen). RNA sequencing was performed at the Center for Applied Genomics
at the Children’s Hospital of Philadelphia per standard protocols. The prepared libraries were
clustered and then sequenced using HiSeq 2000 sequencer (Illumina, Inc., San Diego, CA, USA)
with four RNA-seq libraries per lane (2 × 101-bp paired-end reads). The RNA-Seq data were
aligned to the hg38 reference genome using GSNAP (version 2016-06-30). The expression of all
genes annotated in the hg38 assembly was quantitated in units of FPKM (fragments per kilobase
exon per million mapped reads) using CUFFQUANT (version 2.2.1), and differential expression
between Normal samples and AMD samples, including assignment of statistical significance, was
assessed for each sample region using CUFFDIFF (version 2.2.1). Using this data, we investigated
the RNA expression of IL1B, NLRP3, and CASP1.
Statistical Analysis
Statistical analyses for each panel are described in figure legends. All statistical analyses were
performed using GraphPad Prism 9.0 (San Diego, CA, USA).
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Figure 5-1. High fat diet induces iron-dependent RPE dysfunction. (A) Mass in grams of mice
fed a low fat diet (LFD) or high fat diet (HFD) alone or in combination with iron chelator, deferiprone
(DFP) (n=20/group). (B) Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT)
hypertrophy were dependent on diet, but not DFP treatment (n=10/group). (C) Diet and DFPtreatment had no effect on glycemic control measured with intraperitoneal glucose tolerance test
(n=10/group). (D) HFD mice accumulate RPE iron, measured using inductively coupled plasma
mass spectrometry, which can be prevented with DFP treatment (n=10/group). (E) HFD mice
accumulate lipid oxidation product MDA in RPE which is rescued by treatment with DFP
(n=10/group). (F) HFD mice RPE upregulate Hmox1, measured by qPCR, in an iron-dependent
manner (n=5/group). (G) HFD mice exhibit c-wave amplitude deficits, measured by
electroretinography, which can be partially rescued by iron chelation with DFP (n=10/group). Data
indicate mean, and where error bars are shown, ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001, by 2-way repeated-measures ANOVA (A,C) or 2-way ANOVA (B,D-G) with Tukey’s HSD
post hoc test.
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Figure 5-2. IL-1β is necessary for HFD-induced RPE iron accumulation and dysfunction. (A)
Human fetal RPE (fRPE) cultures were treated with either transferrin bound ferric iron (Tf•55Fe3+)
or ferrous iron ascorbate (55Fe2+) alone or in the presence of recombinant IL-1β (rIL-1β).
Intracellular iron accumulation in fRPE lysates was measured 8 hours of treatment using a
scintillation counter to quantify counts per minute (CPM) (n=3/group). (B) Human fetal RPE (fRPE)
cultures were treated with either media (vehicle) or recombinant IL-1β (rIL-1β) for 8 hours before
cells were harvested for qPCR analysis of iron transport/regulatory genes (n=6/group). (C) Mass in
grams of WT and Il1b-/- (KO) mice fed a low fat diet (LFD) or high fat diet (HFD) (n=20/group). (D)
Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) hypertrophy were
dependent on diet, but not genotype (n=10/group). (E) Diet and genotype had no effect on glycemic
control measured with intraperitoneal glucose tolerance test (n=10/group). (F) RPE gene
expression measured by qPCR following 12 weeks of either LFD or HFD (n=5/group). (G) Retinal
CD11b+ cell gene expression following 12 weeks of either LFD or HFD (n=5/group). (H) HFD WT
mice accumulate RPE iron, measured using inductively coupled plasma mass spectrometry, which
is rescued in the HFD Il1b-/- mice (n=10/group). (I) HFD WT mice accumulate lipid oxidation
product MDA in RPE which is rescued in HFD Il1b-/- mice (n=10/group). (J) HFD WT mice RPE
upregulate Hmox1 in an Il1b-dependent manner (n=5/group). (K) HFD WT mice exhibit c-wave
amplitude deficits, measured by electroretinography, which is rescued in HFD Il1b-/- mice
(n=10/group). Data indicate mean, and where error bars are shown, ± SD. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001, by 1-way ANOVA with multiple comparisons (A), unpaired student’s
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t-test (B), or 2-way repeated-measures ANOVA (C,E) or 2-way ANOVA (D,F-K) with Tukey’s HSD
post hoc test.
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Figure 5-3. Activation of systemic and local inflammatory circuits contribute to IL-1β
production. (A) Schematic of RPE exposed apically to the neurosensory retina behind the bloodretina barrier, and the fenestrated choriocapillaris basolaterally. (B) IL-1β ELISA performed on
epididymal white adipose tissue (eWAT), retina, choroid and serum harvested from WT mice fed a
LFD or HFD diet for 12 weeks (n=10/group). (C-D) qPCR analysis of Il1b, Nlrp3, and Casp1 gene
expression in retinal (C) and choroidal (D) CD11b+ cells (n=5/group). (E) Schematic of eWAT
transplant. (F-H) IL-1β ELISA performed on serum (F), choroid (G), or retina (H) from WT mice fed
a LFD or HFD that underwent a sham transplant surgery (Sh.) or Il1b-/- mice fed a high fat diet that
received eWAT donor tissue from HFD-fed WT or Il1b-/- mice (n=10/group). (I) iCP-MS performed
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on RPE isolated from WT mice fed a LFD or HFD that underwent a sham transplant surgery (Sh.)
or Il1b-/- mice fed a high fat diet that received eWAT donor tissue from HFD-fed WT or Il1b-/- mice
(n=10/group). (J) Schematic of intravitreal injection. (K) WT mice received an intravitreal injection
of PBS or recombinant IL-1β (rIL-1β). 8 hours after injection, RPE was harvested and intracellular
iron was quantified using iCP-MS (n =10/group). Data indicate mean. *P < 0.05, **P < 0.01, ****P
< 0.0001, by unpaired student’s t-test (B-D. K), or 2-way ANOVA (F-I) with Tukey’s HSD post hoc
test.
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Figure 5-4. Hallmarks of IL-1β-dependent CISR are observed in AMD patients. (A) Human
choroidal single-cell RNA sequencing data (Voigt et al., 2019, 2020a) were reanalyzed. Cells
expressing at least one read of IL1B, NLRP3, and CASP1 (i.e., triple-positive cells) were colored
in red, while the remaining cells were colored in grey. A total of 59% of macrophages expressed
IL1B, NLRP3, and CASP1. (B) Violin plots of IL1B, NLRP3, and CASP1 indicate macrophagespecific expression of these transcripts. (C) Using the same single-cell RNA sequencing data,
differential expression analysis was performed between macrophages originating from AMD
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donors (n = 2) versus adult control donors (n = 4). Differential expression results are displayed in
a volcano plot, where positive log fold-changes indicate enrichment in AMD samples. Results for
IL1B, CASP1, and NLRP3 are highlighted. (D) Visualization of human neurosensory retina singlecell clusters using t-SNE. Cells are colored by cell type. sequencing data from normal retinas. (E)
Cells from panel D that expressed IL1B were colored in purple. (F) Cells from panel D that
expressed NLRP3 were colored in purple. (G) Cells from panel D that expressed CASP1 were
colored in purple. (H) Cells from panel D that expressed HAMP were colored in purple. (I) Bulk
neurosensory retina RNAseq on normal, early AMD and late AMD macular retina (MR) or peripheral
retina (PR) showing expression of IL1B, NLRP3, and CASP1 across disease progression in a
region-specific manner. Color scale corresponds to log10 of expression measured in FPKM. (J) IL1β ELISA performed on neurosensory retina from eyes without AMD (MGS1, n=6) and with early
(MGS2, n=6) or intermediate (MGS3, n=6) AMD. See Supplemental Table 1 for donor information.
**P < 0.01 by unpaired student’s t-test (J).
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MGSB

Age (Yrs.)

Sex

Time (Hrs.)C

Cause of Death

Donor 1

1

75

F

20.9

Aspiration Pneumonia

Donor 2

1

79

F

14.7

Pulseless Electrical Activity Arrest

Donor 3

1

73

F

20.7

Sarcoma of the Lung

Donor 4

1

76

M

21.9

Cardiac Arrest

Donor 5

1

77

M

16.1

Congestive Heart Failure

Donor 6

1

78

M

19.6

Abdominal Aortic Aneurysm

Donor 7

2

72

M

20.3

Bowel Perforation

Donor 8

2

75

F

22.2

Pulmonary Fibrosis

Donor 9

2

71

F

13.3

Congestive Heart Failure

Donor 10

2

75

M

23.1

End Stage Renal Disease

Donor 11

2

72

M

24.6

Pulmonary Embolism

Donor 12

2

75

M

13.3

Anoxic Brain Injury

Donor 13

3

75

F

19.0

Pneumonia

Donor 14

3

78

F

18.8

Lung Cancer

Donor 15

3

80

M

20.0

Acute Cardiac Event

Donor 16

3

82

F

22.2

Trauma

Donor 17

3

75

M

20.6

Congestive Heart Failure

Donor 18

3

83

F

12.9

Cardiogenic Shock

Supplemental Table 5-1. Donor Characteristics and Clinical Information
A
Information supplied by Lions Gift of Sight, St. Paul, MN (formerly known as Minnesota Lions
Eye Bank).
B
Minnesota Grading Scale (MGS)
C
The time from death to tissue freezing.
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CHAPTER 6: FUTURE DIRECTIONS
Future Directions Studying GLP-1R Agonists for Retinal Disease
NLY01-Mediated Rescue of Retinal Ganglion Cells
In our study, retinal ganglion cell (RGC) survival was quantified using Brn3a+ and Rbpms+ soma
counting in whole retinal flatmounts. RGC degeneration occurs in retrograde fashion. Loss of the
RGC soma is a late step in degeneration. It is possible that NLY01 slowed RGC degeneration,
increasing the number of RGC somas present at the 6-week time point but overestimating longterm survival. To address this limitation of our study, future work should count optic nerve axons
and axon termini in the lateral geniculate nucleus to determine if NLY01 slows or prevents
degeneration. Furthermore, microelectrode array recordings should be used to determine if the
surviving RGCs are electrically functionally and if NLY01 preferentially spares a particular subset
of RGCs.
Delineating NLY01’s Mechanism of Action
Previous in vitro work has shown that NLY01 acts on microglial GLP-1R to reduce NFkB
translocation to the nucleus and upregulate Nfkbia, which encodes NFkB inhibitor alpha. However,
the mechanism of NLY01-mediated neuroprotection has not been shown in vivo. Our data suggest
that the in vitro effect of NLY01, reducing NFkB translocation and upregulating Nfkbia, occurs in
retinal CD11b+ cells. Future work should interrogate this mechanism using Glp1r (fl/fl) and Glp1r
(stop-fl/stop-fl) mice to selectively ablate and restore Glp1r expression in macrophages (with Cxcr4CreER), microglia (with Tmem119-CreER) and both cell populations (with Cx3cr1-CreER).
Broadening the Scope of GLP-1R Neuroprotection
In our study we tested one drug, NLY01, delivered intraperitoneally. However, NLY01 belongs to a
class of therapeutics called glucagon-like peptide 1 receptor (GLP-1R) agonists which includes
FDA-approved exenatide, liraglutide, albiglutide, dulaglutide, semaglutide, and lixisenatide. Future
work should test the efficacy of other members of the GLP-1R agonist class in the microbeadinduced glaucoma mouse model, as well as other routes of administration.
Testing Efficacy of NLY01 in Other Glaucoma Mouse Models
Glaucoma itself is a diverse syndrome, encompassing optic neuropathies of multiple etiologies. To
enhance the translational potential of NLY01, future work should test the efficacy of NLY01 in other
mouse models of glaucoma, including the DBA/2J mouse model of hereditary glaucoma, and the
MTCO1 mouse model of normotensive glaucoma.
American Academy of Ophthalmology IRIS Database Study
In Chapter 2, we use a retrospective observational study to test the association between GLP-1R
agonist exposure and new glaucoma diagnoses. While we found a statistically significant reduction
in the hazard of a new glaucoma diagnosis among exposed individuals, our analysis identified only
68 patients across both the unexposed and exposed cohorts who met outcome criteria. Future work
using the American Academy of Ophthalmology IRIS registry would allow us to test the association
between GLP-1R exposure and glaucoma incidence as well as glaucoma progression in a larger
population with extensive ophthalmic data. Such a study would also allow us to determine the
magnitude of glaucoma risk reduction among diabetic patients exposed to GLP-1R agonists relative
to both unexposed controls and the general population. This would provide a more complete
assessment of how GLP-1R exposure influences glaucoma risk.
Following Up the Cellular Iron Sequestration Response
Brain
Future work should interrogate the mechanism by which trans-IL-6 signaling triggers transcription
of the CISR genes. Additionally, follow up studies should be performed to determine (1) which
cytokines contribute to glial CISR, (2) the effect of iron chelation on glial activation states, and (3)
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whether targeting glial iron accumulation can ameliorate the deleterious effects of
neuroinflammation in neurodegenerative disease.
Our study focused on the PFF-induced model of sporadic Parkinson’s disease (PD). Specifically
looking at deficits observed at the 6-month post-injection time point. Additional studies, looking at
the potential protective effects of DFP in this model should examine later time points to determine
if the treatment effect size improves as the mice age and PFF-induced deficits become more
severe.
Finally, future work should look for the CISR gene signature and iron accumulation in other
diseases of neuroinflammation and iron dyshomeostasis, including Alzheimer’s disease,
amyotrophic lateral sclerosis and multiple sclerosis.
Retina
Our work links IL-1β to RPE iron accumulation. IL-1β is a broadly acting pro-inflammatory cytokine
that can exert effects across multiple maladaptive and adaptive pathways. Among those pathways,
IL-1β has been implicated in VEGF-induced neovascularization, a critical feature of wet AMD.
Future work should examine the role of IL-1β production in the conversion from non-neovascular
to neovascular AMD. If IL-1β contributes to neovascularization in AMD, anti-IL-1β therapies,
already FDA-approved for systemic delivery in autoimmune disease, could be repurposed for
intravitreal delivery. This group of therapeutics could be used alongside the AREDS supplement to
reduce the rate of neovascular conversion and in turn prevent retinal degeneration.
Although the RPE of the HFD mice did not upregulate Il1b, Nlrp3 or Casp1, AMD RPE could serve
as a source of IL-1β. RPE-derived IL-1β could act in an autocrine fashion, triggering RPE CISR.
Since iron itself is capable of activating the RPE inflammasome, autocrine RPE IL-1β signaling
could trigger a vicious cycle of iron and inflammation leading to RPE degeneration. Future work
should examine the expression of these three genes in AMD RPE and mouse models of AMD to
determine if RPE could contribute to retinal IL-1β production in AMD.
Our data implicate obesity and inflammatory adipose tissue in activation of the RPE CISR and RPE
iron accumulation. However, we did not explore whether weight loss could reverse RPE CISR and
restore RPE function. Future work in mice should test the efficacy of a low fat diet in reversing the
systemic inflammation and RPE CISR observed in mice fed a high fat diet.
Additionally, we chose to focus our work on the RPE, however CISR may occur in other cells types,
including the photoreceptors, which have previously been shown to exhibit iron accumulation in
AMD. CISR in microglia may also lead to further inflammation based on previous work showing
that iron accumulation leads to microglial production of pro-inflammatory cytokines. These potential
lines of inquiry highlight the diverse functions of the CISR across different retinal cell types and
emphasize the need for additional work characterizing the CISR.
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